<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="424e41da-dc3a-4605-8358-57db40ab8eb1"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>These highlights do not include all the information needed to use INTUNIV<sup>®</sup> safely and effectively. See full prescribing information for INTUNIV.<br/>
      <br/>INTUNIV<sup>®</sup> (guanfacine) extended-release tablets, for oral use<br/>Initial U.S. Approval: 1986</title>
   <effectiveTime value="20250508"/>
   <setId root="b972af81-3a37-40be-9fe1-3ddf59852528"/>
   <versionNumber value="42"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="039997266" root="1.3.6.1.4.1.519.1"/>
            <name>Takeda Pharmaceuticals America, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="436796809" root="1.3.6.1.4.1.519.1"/>
                        <name>Industriale Chimica SRL</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-513" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-515" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-517" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-519" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="014167995" root="1.3.6.1.4.1.519.1"/>
                        <name>Catalent Pharma Solutions, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-513" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-515" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-517" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-519" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="756003745" root="1.3.6.1.4.1.519.1"/>
                        <name>Mayne Pharma International Pty Ltd.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-513" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-515" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-517" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-519" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="079415560" root="1.3.6.1.4.1.519.1"/>
                        <name>Patheon Manufacturing Services LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="ANALYSIS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-513" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="ANALYSIS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-515" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="ANALYSIS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-517" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="ANALYSIS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-519" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="LABEL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-513" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="LABEL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-515" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="LABEL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-517" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="LABEL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-519" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="MANUFACTURE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-513" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="MANUFACTURE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-515" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="MANUFACTURE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-517" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="MANUFACTURE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-519" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="MANUFACTURE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-520" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="PACK" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-513" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="PACK" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-515" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="PACK" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-517" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="PACK" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-519" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="460054141" root="1.3.6.1.4.1.519.1"/>
                        <name>Quimica Sintetica S.A.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" displayName="API MANUFACTURE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-513" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" displayName="API MANUFACTURE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-515" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" displayName="API MANUFACTURE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-517" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" displayName="API MANUFACTURE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-519" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="143696495" root="1.3.6.1.4.1.519.1"/>
                        <name>Sharp Packaging Services, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="PACK" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-513" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="PACK" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-515" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="PACK" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-517" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="PACK" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-519" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="LABEL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-513" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="LABEL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-515" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="LABEL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-517" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="LABEL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-519" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84382" displayName="STERILIZE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-513" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84382" displayName="STERILIZE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-515" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84382" displayName="STERILIZE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-517" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84382" displayName="STERILIZE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-519" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="002346625" root="1.3.6.1.4.1.519.1"/>
                        <name>Sharp Packaging Services, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="PACK" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-513" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="PACK" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-515" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="PACK" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-517" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="PACK" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-519" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="LABEL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-513" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="LABEL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-515" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="LABEL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-517" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="LABEL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-519" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="878839106" root="1.3.6.1.4.1.519.1"/>
                        <name>Pharmazell (India) Private Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" displayName="API MANUFACTURE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-513" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" displayName="API MANUFACTURE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-515" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" displayName="API MANUFACTURE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-517" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" displayName="API MANUFACTURE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54092-519" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="b9793af4-bcfc-4c58-8ca6-3c7d4c22269a"/>
               <code code="48780-1" displayName="SPL PRODUCT DATA ELEMENTS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250408"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="54092-513" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Intuniv</name>
                        <formCode code="C42927" displayName="TABLET, EXTENDED RELEASE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>guanfacine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="1"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="PML56A160O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GUANFACINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="30OMY4G3MK" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>GUANFACINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Z78RG6M2N2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2208 (15000 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="68401960MK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE (120 .MU.M)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="74G4R6TH13" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:1)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R8WTH25YS2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERYL DIBEHENATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="88XHZ13131" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FUMARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54092-513-02" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20090902"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="7"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54092-513-03" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20090902"/>
                                    <high value="20151029"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA022037" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20090902"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="WHITE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText>white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">503;1mg</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" displayName="ROUND" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="7" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="54092-515" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Intuniv</name>
                        <formCode code="C42927" displayName="TABLET, EXTENDED RELEASE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>guanfacine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="2"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="PML56A160O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GUANFACINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="30OMY4G3MK" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>GUANFACINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Z78RG6M2N2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2208 (15000 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="68401960MK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE (120 .MU.M)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="74G4R6TH13" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:1)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R8WTH25YS2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERYL DIBEHENATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="88XHZ13131" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FUMARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54092-515-02" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20090902"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="7"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54092-515-03" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20090902"/>
                                    <high value="20151029"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA022037" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20090902"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="WHITE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText>white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">503;2mg</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" displayName="OVAL" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="12" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="54092-517" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Intuniv</name>
                        <formCode code="C42927" displayName="TABLET, EXTENDED RELEASE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>guanfacine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="3"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="PML56A160O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GUANFACINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="30OMY4G3MK" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>GUANFACINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Z78RG6M2N2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2208 (15000 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="68401960MK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE (120 .MU.M)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="74G4R6TH13" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:1)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R8WTH25YS2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERYL DIBEHENATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="88XHZ13131" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FUMARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54092-517-02" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20090902"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="7"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54092-517-03" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20090902"/>
                                    <high value="20151029"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA022037" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20090902"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48329" displayName="GREEN" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText>green</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">503;3mg</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" displayName="ROUND" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="8" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="54092-519" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Intuniv</name>
                        <formCode code="C42927" displayName="TABLET, EXTENDED RELEASE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>guanfacine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="4"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="PML56A160O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GUANFACINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="30OMY4G3MK" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>GUANFACINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Z78RG6M2N2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2208 (15000 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="68401960MK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE (120 .MU.M)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="74G4R6TH13" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:1)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R8WTH25YS2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERYL DIBEHENATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="88XHZ13131" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FUMARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54092-519-02" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20090902"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA022037" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20090902"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48329" displayName="GREEN" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE">
                              <originalText>green</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">503;4mg</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" displayName="OVAL" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="12" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="54092-520" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Intuniv</name>
                        <formCode code="C47916" displayName="KIT" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>guanfacine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54092-520-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43197" displayName="KIT" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20090902"/>
                                    <high value="20151029"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator unit="1" value="7"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <name>Intuniv</name>
                              <formCode code="C42927" displayName="TABLET, EXTENDED RELEASE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>guanfacine</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIM">
                                 <quantity>
                                    <numerator unit="mg" value="1"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="PML56A160O" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>GUANFACINE HYDROCHLORIDE</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="30OMY4G3MK" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>GUANFACINE</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="Z78RG6M2N2" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYPROMELLOSE 2208 (15000 MPA.S)</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LACTOSE MONOHYDRATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POVIDONE, UNSPECIFIED</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="68401960MK" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CROSPOVIDONE (120 .MU.M)</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="74G4R6TH13" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:1)</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MICROCRYSTALLINE CELLULOSE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="R8WTH25YS2" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>GLYCERYL DIBEHENATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="88XHZ13131" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FUMARIC ACID</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="7"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA022037" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20090902"/>
                                    <high value="20151029"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48325" displayName="WHITE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="ST">503;1mg</value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value value="1" xsi:type="INT"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48348" displayName="ROUND" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value unit="mm" value="7" xsi:type="PQ"/>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator unit="1" value="7"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <name>Intuniv</name>
                              <formCode code="C42927" displayName="TABLET, EXTENDED RELEASE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>guanfacine</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIM">
                                 <quantity>
                                    <numerator unit="mg" value="2"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="PML56A160O" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>GUANFACINE HYDROCHLORIDE</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="30OMY4G3MK" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>GUANFACINE</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="Z78RG6M2N2" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYPROMELLOSE 2208 (15000 MPA.S)</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LACTOSE MONOHYDRATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POVIDONE, UNSPECIFIED</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="68401960MK" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CROSPOVIDONE (120 .MU.M)</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="74G4R6TH13" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:1)</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MICROCRYSTALLINE CELLULOSE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="R8WTH25YS2" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>GLYCERYL DIBEHENATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="88XHZ13131" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FUMARIC ACID</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="7"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA022037" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20090902"/>
                                    <high value="20151029"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48325" displayName="WHITE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="ST">503;2mg</value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value value="1" xsi:type="INT"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48345" displayName="OVAL" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value unit="mm" value="12" xsi:type="PQ"/>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA022037" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="completed"/>
                           <effectiveTime>
                              <low value="20090902"/>
                              <high value="20151029"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="effe3426-0228-4f39-9f87-07a3996bb4ca"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>INTUNIV<sup>® </sup>is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250408"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>INTUNIV<content styleCode="bold"/> is a central alpha<sub>2A</sub>-adrenergic receptor agonist indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications (<linkHtml href="#S1">1</linkHtml>,<linkHtml href="#S14">14</linkHtml>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="ef570350-6db2-4686-a1ec-88f8cf4407d3"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250408"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item> Recommended dose: 1 mg to 7 mg (0.05 to 0.12 mg/kg target weight based dose range) once daily in the morning or evening based on clinical response and tolerability (<linkHtml href="#S2.2">2.2</linkHtml>).</item>
                           <item> Begin at a dose of 1 mg once daily and adjust in increments of no more than 1 mg/week (<linkHtml href="#S2.2">2.2</linkHtml>).</item>
                           <item> Do not crush, chew or break tablets before swallowing (<linkHtml href="#S2.1">2.1</linkHtml>).</item>
                           <item>Do not administer with high-fat meals, because of increased exposure (<linkHtml href="#S2.1">2.1</linkHtml>).</item>
                           <item>Do not substitute for immediate-release guanfacine tablets on a mg-per-mg basis, because of differing pharmacokinetic profiles (<linkHtml href="#S2.3">2.3</linkHtml>).</item>
                           <item>If switching from immediate-release guanfacine, discontinue that treatment and titrate with INTUNIV<content styleCode="bold"/> as directed (<linkHtml href="#S2.3">2.3</linkHtml>).</item>
                           <item>When discontinuing, taper the dose in decrements of no more than 1 mg every 3 to 7 days to avoid rebound hypertension (<linkHtml href="#S2.5">2.5</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="c709a89b-1a50-4638-91e9-00f0982022f8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 General Instruction for Use</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Swallow tablets whole. Do not crush, chew, or break tablets because this will increase the rate of guanfacine release. </content>Do not administer with high fat meals, due to increased exposure.</paragraph>
                     </text>
                     <effectiveTime value="20250408"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="2a0c9d9e-f82f-43bc-869d-08bface5705b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Dose Selection</title>
                     <text>
                        <paragraph>Take INTUNIV orally once daily, either in the morning or evening, at approximately the same time each day. Begin at a dose of 1 mg/day, and adjust in increments of no more than 1 mg/week.</paragraph>
                        <paragraph>In monotherapy clinical trials, there was dose- and exposure-related clinical improvement as well as risks for several clinically significant adverse reactions (hypotension, bradycardia, sedative events). To balance the exposure-related potential benefits and risks, the recommended target dose range depending on clinical response and tolerability for INTUNIV is 0.05 to 0.12 mg/kg/day (total daily dose between 1 to 7 mg) (See <linkHtml href="#table1">Table 1</linkHtml>).</paragraph>
                        <table width="75%" ID="table1">
                           <caption>Table 1: Recommended Target Dose Range for Therapy with INTUNIV
									</caption>
                           <col width="34%" align="left" valign="top"/>
                           <col width="66%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule" align="center">Weight</th>
                                 <th styleCode="Rrule">Target dose range (0.05 to 0.12 mg/kg/day)</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td align="left" valign="top" colspan="2">Doses above 4 mg/day have not been evaluated in children (ages 6 to 12 years) and doses above 7 mg/day have not been evaluated in adolescents (ages 13 to 17 years)</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">25 to 33.9 kg</td>
                                 <td styleCode="Rrule">2 to 3 mg/day</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">34 to 41.4 kg</td>
                                 <td styleCode="Rrule">2 to 4 mg/day</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">41.5 to 49.4 kg</td>
                                 <td styleCode="Rrule">3 to 5 mg/day</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">49.5 to 58.4 kg</td>
                                 <td styleCode="Rrule">3 to 6 mg/day</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">58.5 to 91 kg</td>
                                 <td styleCode="Rrule">4 to 7 mg/day</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">&gt;91 kg</td>
                                 <td styleCode="Rrule">5 to 7 mg/day</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In the adjunctive trial which evaluated INTUNIV treatment with psychostimulants, the majority of patients reached optimal doses in the 0.05 to 0.12 mg/kg/day range. Doses above 4 mg/day have not been studied in adjunctive trials.</paragraph>
                     </text>
                     <effectiveTime value="20250408"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="2250dd66-d8c8-4350-9081-45d3958ae6b6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Switching from Immediate-Release Guanfacine to INTUNIV
							</title>
                     <text>
                        <paragraph>If switching from immediate-release guanfacine, discontinue that treatment, and titrate with INTUNIV following above recommended schedule.</paragraph>
                        <paragraph>Do not substitute for immediate-release guanfacine tablets on a milligram-per-milligram basis, because of differing pharmacokinetic profiles. INTUNIV has significantly reduced C<sub>max</sub> (60% lower), bioavailability (43% lower), and a delayed T<sub>max</sub> (3 hours later) compared to those of the same dose of immediate-release guanfacine <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250408"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="42324817-048a-42e1-9998-023b7286fd3a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Maintenance Treatment</title>
                     <text>
                        <paragraph>Pharmacological treatment of ADHD may be needed for extended periods.  Healthcare providers should periodically re-evaluate the long-term use of INTUNIV, and adjust weight-based dosage as needed.  The majority of children and adolescents reach optimal doses in the 0.050.12 mg/kg/day range.  Doses above 4 mg/day have not been evaluated in children (ages 6 to 12 years) and above 7 mg/day have not been evaluated in adolescents (ages 13 to 17 years) <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250408"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.5">
                     <id root="a9c17dc6-a0da-46d2-af8e-598896a66c44"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Discontinuation of Treatment</title>
                     <text>
                        <paragraph>Following discontinuation of INTUNIV, patients may experience increases in blood pressure and heart rate <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml> and <linkHtml href="#S6">Adverse Reactions (6)</linkHtml>]</content>. Patients/caregivers should be instructed not to discontinue INTUNIV without consulting their health care provider. Monitor blood pressure and pulse when reducing the dose or discontinuing the drug. Taper the daily dose in decrements of no more than 1 mg every 3 to 7 days to minimize the risk of rebound hypertension. 								</paragraph>
                     </text>
                     <effectiveTime value="20250408"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.6">
                     <id root="0291973e-6507-4d03-8dbe-a0b503633ae6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 Missed Doses</title>
                     <text>
                        <paragraph>When reinitiating patients to the previous maintenance dose after two or more missed consecutive doses, consider titration based on patient tolerability.</paragraph>
                     </text>
                     <effectiveTime value="20250408"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.7">
                     <id root="8559592a-3a12-45cc-85ee-fcac2d2280f1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.7 Dosage Adjustment with Concomitant Use of Strong and Moderate CYP3A4 Inhibitors or Inducers</title>
                     <text>
                        <paragraph>									Dosage adjustments for INTUNIV are recommended with concomitant use of strong and moderate CYP3A4 inhibitors (e.g., ketoconazole), or CYP3A4 inducers (e.g., carbamazepine) (Table 2) <content styleCode="italics">[see <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>. 								</paragraph>
                        <table width="75%" ID="table2">
                           <caption>Table 2: INTUNIV Dosage Adjustments for Patients Taking Concomitant CYP3A4 Inhibitors or Inducers</caption>
                           <col width="25%" align="left" valign="top"/>
                           <col width="25%" align="left" valign="top"/>
                           <col width="25%" align="left" valign="top"/>
                           <col width="25%" align="left" valign="top"/>
                           <thead>
                              <tr styleCode="Botrule">
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule" colspan="3" align="center">Clinical Scenarios</th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule">Starting INTUNIV while currently on a CYP3A4 modulator</th>
                                 <th styleCode="Rrule">Continuing  INTUNIV while adding a CYP3A4 modulator</th>
                                 <th styleCode="Rrule">Continuing INTUNIV while stopping a CYP3A4 modulator</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">CYP3A4<br/>Strong and moderate Inhibitors</content>
                                 </td>
                                 <td styleCode="Rrule">
                                    <content styleCode="bold">Decrease</content> INTUNIV dosage to half the recommended level.<br/>(see <linkHtml href="#table1">Table 1</linkHtml>)</td>
                                 <td styleCode="Rrule">
                                    <content styleCode="bold">Decrease</content> INTUNIV dosage to half the recommended level.<br/>(see <linkHtml href="#table1">Table 1</linkHtml>)</td>
                                 <td styleCode="Rrule">
                                    <content styleCode="bold">Increase</content> INTUNIV dosage to recommended level.<br/>(see <linkHtml href="#table1">Table 1</linkHtml>)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">CYP3A4<br/>Strong and moderate Inducers</content>
                                 </td>
                                 <td styleCode="Rrule">
                                    <content styleCode="bold"> Consider increasing</content> INTUNIV dosage up to double the recommended level.<br/>(see <linkHtml href="#table1">Table 1</linkHtml>)<br/>
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule">
                                    <content styleCode="bold">Consider increasing</content> INTUNIV dosage up to double the recommended level over 1 to 2 weeks.<br/>(see <linkHtml href="#table1">Table 1</linkHtml>)<br/>
                                 </td>
                                 <td styleCode="Rrule">
                                    <content styleCode="bold">Decrease</content> INTUNIV dosage to recommended level over 1 to 2 weeks.<br/>(see <linkHtml href="#table1">Table 1</linkHtml>)</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250408"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="a8defb54-7d03-40b5-9bec-f91330714716"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>1 mg, 2 mg, 3 mg, and 4 mg extended-release tablets</paragraph>
               </text>
               <effectiveTime value="20250408"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Extended-release tablets: 1 mg, 2 mg, 3 mg, and 4 mg (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="10ff9bd8-e2fb-4a63-9f27-eb04028dd6cb"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>INTUNIV is contraindicated in patients with a history of a hypersensitivity reaction to INTUNIV or its inactive ingredients, or other products containing guanfacine. Rash and pruritus have been reported.</paragraph>
               </text>
               <effectiveTime value="20250408"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>History of hypersensitivity to INTUNIV<content styleCode="bold"/>, its inactive ingredients, or other products containing guanfacine (<linkHtml href="#S4">4</linkHtml>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="c2bbe13d-b070-42c2-a741-cefcb1980348"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250408"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Hypotension, bradycardia, syncope: Titrate slowly and monitor vital signs frequently in patients at risk for hypotension, heart block, bradycardia, syncope, cardiovascular disease, vascular disease, cerebrovascular disease or chronic renal failure. Measure heart rate and blood pressure prior to initiation of therapy, following dose increases, and periodically while on therapy. Avoid concomitant use of drugs with additive effects unless clinically indicated. Advise patients to avoid becoming dehydrated or overheated (<linkHtml href="#S5.1">5.1</linkHtml>).</item>
                           <item>Sedation and somnolence: Occur commonly with INTUNIV<content styleCode="bold"/>. Consider the potential for additive sedative effects with CNS depressant drugs. Caution patients against operating heavy equipment or driving until they know how they respond to INTUNIV<content styleCode="bold"/> (<linkHtml href="#S5.2">5.2</linkHtml>).</item>
                           <item>Cardiac Conduction Abnormalities: May worsen sinus node dysfunction and atrioventricular (AV) block, especially in patients taking other sympatholytic drugs. Titrate slowly and monitor vital signs frequently (<linkHtml href="#S5.3">5.3</linkHtml>).</item>
                           <item>Rebound Hypertension: Abrupt discontinuation of INTUNIV can lead to clinically significant and persistent rebound hypertension. Subsequent hypertensive encephalopathy was also reported. To minimize the risk of  rebound hypertension upon discontinuation, the total daily dose of INTUNIV should be tapered in decrements of no more than 1 mg every 3 to 7 days (<linkHtml href="#S5.4">5.4</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="4dc25eca-73f2-48e3-8fca-ffe084434df6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Hypotension, Bradycardia, and Syncope</title>
                     <text>
                        <paragraph>Treatment with INTUNIV can cause dose-dependent decreases in blood pressure and heart rate. Decreases were less pronounced over time of treatment. Orthostatic hypotension and syncope have been reported <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>.</paragraph>
                        <paragraph>Measure heart rate and blood pressure prior to initiation of therapy, following dose increases, and periodically while on therapy. Titrate INTUNIV slowly in patients with a history of hypotension, and those with underlying conditions that may be worsened by hypotension and bradycardia; e.g., heart block, bradycardia, cardiovascular disease, vascular disease, cerebrovascular disease, or chronic renal failure. In patients who have a history of syncope or may have a condition that predisposes them to syncope, such as hypotension, orthostatic hypotension, bradycardia, or dehydration, advise patients to avoid becoming dehydrated or overheated. Monitor blood pressure and heart rate, and adjust dosages accordingly in patients treated concomitantly with antihypertensives or other drugs that can reduce blood pressure or heart rate or increase the risk of syncope.</paragraph>
                     </text>
                     <effectiveTime value="20250408"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="5301976e-c8b5-4482-87b8-ebed3a4c84f4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Sedation and Somnolence</title>
                     <text>
                        <paragraph>Somnolence and sedation were commonly reported adverse reactions in clinical studies <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>. Before using INTUNIV with other centrally active depressants, consider the potential for additive sedative effects. Caution patients against operating heavy equipment or driving until they know how they respond to treatment with INTUNIV<content styleCode="italics">.</content> Advise patients to avoid use with alcohol.</paragraph>
                     </text>
                     <effectiveTime value="20250408"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="d71f5832-b42e-448a-8781-f833a4218645"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 	Cardiac Conduction Abnormalities</title>
                     <text>
                        <paragraph>The sympatholytic action of INTUNIV may worsen sinus node dysfunction and atrioventricular (AV) block, especially in patients taking other sympatholytic drugs. Titrate INTUNIV slowly and monitor vital signs frequently in patients with cardiac conduction abnormalities or patients concomitantly treated with other sympatholytic drugs.</paragraph>
                     </text>
                     <effectiveTime value="20250408"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="606f5a47-1810-4b5e-a16a-dc99aa963e60"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4	Rebound Hypertension</title>
                     <text>
                        <paragraph>In post marketing experience, abrupt discontinuation of INTUNIV has resulted in clinically significant and persistent rebound hypertension above baseline levels and increases in heart rate. Hypertensive encephalopathy has also been reported in association with rebound hypertension with both INTUNIV and immediate release guanfacine <content styleCode="italics">[see <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>]</content>. In these cases, high-dosage guanfacine was discontinued; concomitant stimulant use was also reported, which may potentially increase hypertensive response upon abrupt discontinuation of guanfacine. Children commonly have gastrointestinal illnesses that lead to vomiting, and a resulting inability to take medications, so they may be especially at risk for rebound hypertension.</paragraph>
                        <paragraph>To minimize the risk of rebound hypertension upon discontinuation, the total daily dose of INTUNIV should be tapered in decrements of no more than 1 mg every 3 to 7 days <content styleCode="italics">[see <linkHtml href="#S2.5">Dosage and Administration (2.5)</linkHtml>]</content>. Blood pressure and heart rate should be monitored when reducing the dose or discontinuing INTUNIV. If abrupt discontinuation occurs (especially with concomitant stimulant use), patients should be closely followed for rebound hypertension.</paragraph>
                     </text>
                     <effectiveTime value="20250408"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="aeb8666b-ab72-4da1-80e5-a906dd871bda"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following serious adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Hypotension, bradycardia, and syncope <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>Sedation and somnolence <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>Cardiac conduction abnormalities <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                     <item>
                        <content styleCode="italics">Rebound Hypertension [see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250408"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (≥5% and at least twice placebo rate) in  fixed-dose monotherapy ADHD trials in children and adolescents (6 to 17 years): hypotension, somnolence, fatigue, nausea, and lethargy (<linkHtml href="#S6.1">6.1</linkHtml>)</paragraph>
                        <paragraph>Flexible dose-optimization ADHD trials in children (6 to 12 years) and adolescents (13 to 17 years): somnolence, hypotension, abdominal pain, insomnia, fatigue, dizziness, dry mouth, irritability, nausea, vomiting, and bradycardia (<linkHtml href="#S6.1">6.1</linkHtml>).</paragraph>
                        <paragraph>Adjunctive treatment to psychostimulant ADHD trial in children and adolescents (6 to 17 years): somnolence, fatigue, insomnia, dizziness, and abdominal pain (<linkHtml href="#S6.1">6.1</linkHtml>).<br/>
                           <br/>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="66b1599b-a2b1-4112-a440-6c41228af975"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The data described below reflect clinical trial exposure to INTUNIV in 2,825 patients. This includes 2,330 patients from completed studies in children and adolescents, ages 6 to 17 years and 495 patients in completed studies in adult healthy volunteers.</paragraph>
                        <paragraph>The mean duration of exposure of 446 patients that previously participated in two 2-year, open-label long-term studies was approximately 10 months.</paragraph>
                     </text>
                     <effectiveTime value="20250408"/>
                     <component>
                        <section>
                           <id root="8de0de30-bc0d-4455-a22b-8ab8166ea78f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Fixed Dose Trials</content>
                              </paragraph>
                              <table width="100%" ID="table3">
                                 <caption>Table 3:  Percentage of Patients Experiencing Most Common (≥5% and at least twice the rate for placebo) Adverse Reactions in Fixed Dose Studies 1 and 2</caption>
                                 <col width="20%" align="left" valign="top"/>
                                 <col width="10%" align="center" valign="top"/>
                                 <col width="10%" align="center" valign="top"/>
                                 <col width="10%" align="center" valign="top"/>
                                 <col width="15%" align="center" valign="top"/>
                                 <col width="15%" align="center" valign="top"/>
                                 <col width="20%" align="center" valign="top"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule"/>
                                       <th styleCode="Rrule" colspan="5">INTUNIV (mg)</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Lrule Rrule" align="center">Adverse Reaction Term</th>
                                       <th styleCode="Rrule">Placebo<br/>(N=149)</th>
                                       <th styleCode="Rrule">1 mg<footnote ID="t3f1">The lowest dose of 1 mg used in Study 2 was not randomized to patients weighing more than 50 kg.</footnote>
                                          <br/>(N=61)</th>
                                       <th styleCode="Rrule">2 mg<br/>(N=150)</th>
                                       <th styleCode="Rrule">3 mg<br/>(N=151)</th>
                                       <th styleCode="Rrule">4 mg<br/>(N=151)</th>
                                       <th styleCode="Rrule">All Doses of INTUNIV (N=513)</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Somnolence<footnote ID="t3fa">The somnolence term includes somnolence, sedation, and hypersomnia.</footnote>
                                       </td>
                                       <td styleCode="Rrule">11%</td>
                                       <td styleCode="Rrule">28%</td>
                                       <td styleCode="Rrule">30%</td>
                                       <td styleCode="Rrule">38%</td>
                                       <td styleCode="Rrule">51%</td>
                                       <td styleCode="Rrule">38%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Fatigue</td>
                                       <td styleCode="Rrule">3%</td>
                                       <td styleCode="Rrule">10%</td>
                                       <td styleCode="Rrule">13%</td>
                                       <td styleCode="Rrule">17%</td>
                                       <td styleCode="Rrule">15%</td>
                                       <td styleCode="Rrule">14%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hypotension<footnote ID="t3fb">The hypotension term includes hypotension, diastolic hypotension, orthostatic hypotension, blood pressure decreased, blood pressure diastolic decreased, blood pressure systolic decreased).</footnote>
                                       </td>
                                       <td styleCode="Rrule">3%</td>
                                       <td styleCode="Rrule">8%</td>
                                       <td styleCode="Rrule">5%</td>
                                       <td styleCode="Rrule">7%</td>
                                       <td styleCode="Rrule">8%</td>
                                       <td styleCode="Rrule">7%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Dizziness</td>
                                       <td styleCode="Rrule">4%</td>
                                       <td styleCode="Rrule">5%</td>
                                       <td styleCode="Rrule">3%</td>
                                       <td styleCode="Rrule">7%</td>
                                       <td styleCode="Rrule">10%</td>
                                       <td styleCode="Rrule">6%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Lethargy</td>
                                       <td styleCode="Rrule">3%</td>
                                       <td styleCode="Rrule">2%</td>
                                       <td styleCode="Rrule">3%</td>
                                       <td styleCode="Rrule">8%</td>
                                       <td styleCode="Rrule">7%</td>
                                       <td styleCode="Rrule">6%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Nausea</td>
                                       <td styleCode="Rrule">2%</td>
                                       <td styleCode="Rrule">7%</td>
                                       <td styleCode="Rrule">5%</td>
                                       <td styleCode="Rrule">5%</td>
                                       <td styleCode="Rrule">6%</td>
                                       <td styleCode="Rrule">6%</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Dry mouth</td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">0%</td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">6%</td>
                                       <td styleCode="Rrule">7%</td>
                                       <td styleCode="Rrule">4%</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <table width="100%" ID="table4">
                                 <caption>Table 4:  Adverse Reactions Leading to Discontinuation (≥2% for all doses of INTUNIV and &gt;rate than in placebo) in Fixed Dose Studies 1 and 2</caption>
                                 <col width="21%" align="left" valign="top"/>
                                 <col width="6%" align="center" valign="top"/>
                                 <col width="6%" align="center" valign="top"/>
                                 <col width="6%" align="center" valign="top"/>
                                 <col width="6%" align="center" valign="top"/>
                                 <col width="6%" align="center" valign="top"/>
                                 <col width="7%" align="center" valign="top"/>
                                 <col width="6%" align="center" valign="top"/>
                                 <col width="7%" align="center" valign="top"/>
                                 <col width="6%" align="center" valign="top"/>
                                 <col width="7%" align="center" valign="top"/>
                                 <col width="8%" align="center" valign="top"/>
                                 <col width="8%" align="center" valign="top"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule" colspan="2"/>
                                       <th styleCode="Rrule" colspan="10">INTUNIV (mg)</th>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule" align="center">Adverse Reaction Term</th>
                                       <th styleCode="Rrule" colspan="2">Placebo<br/>(N=149)</th>
                                       <th styleCode="Rrule" colspan="2">1 mg<footnote ID="t4f1">The lowest dose of 1 mg used in Study 2 was not randomized to patients weighing more than 50 kg.</footnote>
                                          <br/>(N=61)</th>
                                       <th styleCode="Rrule" colspan="2">2 mg<br/>(N=150)</th>
                                       <th styleCode="Rrule" colspan="2">3 mg<br/>(N=151)</th>
                                       <th styleCode="Rrule" colspan="2">4 mg<br/>(N=151)</th>
                                       <th styleCode="Rrule" colspan="2">All Doses of INTUNIV (N=513)</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Lrule Rrule"/>
                                       <th>n</th>
                                       <th styleCode="Rrule">(%)</th>
                                       <th>n</th>
                                       <th styleCode="Rrule">(%)</th>
                                       <th>n</th>
                                       <th styleCode="Rrule">(%)</th>
                                       <th>n</th>
                                       <th styleCode="Rrule">(%)</th>
                                       <th>n</th>
                                       <th styleCode="Rrule">(%)</th>
                                       <th>n</th>
                                       <th styleCode="Rrule">(%)</th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td align="left" valign="top" colspan="13">Adverse reactions leading to discontinuation in ≥2% in any dose group but did not meet this criteria in all doses combined: hypotension (hypotension, diastolic hypotension, orthostatic hypotension, blood pressure decreased, blood pressure diastolic decreased, blood pressure systolic decreased), headache, and dizziness.</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Total patients</td>
                                       <td>4</td>
                                       <td styleCode="Rrule">(3%)</td>
                                       <td>2</td>
                                       <td styleCode="Rrule">(3%)</td>
                                       <td>10</td>
                                       <td styleCode="Rrule">(7%)</td>
                                       <td>15</td>
                                       <td styleCode="Rrule">(10%)</td>
                                       <td>27</td>
                                       <td styleCode="Rrule">(18%)</td>
                                       <td>54</td>
                                       <td styleCode="Rrule">(11%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Somnolence<footnote ID="t4fa">The somnolence term includes somnolence, sedation, and hypersomnia.</footnote>
                                       </td>
                                       <td>1</td>
                                       <td styleCode="Rrule">(1%)</td>
                                       <td>2</td>
                                       <td styleCode="Rrule">(3%)</td>
                                       <td>5</td>
                                       <td styleCode="Rrule">(3%)</td>
                                       <td>6</td>
                                       <td styleCode="Rrule">(4%)</td>
                                       <td>17</td>
                                       <td styleCode="Rrule">(11%)</td>
                                       <td>30</td>
                                       <td styleCode="Rrule">(6%)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Fatigue</td>
                                       <td>0</td>
                                       <td styleCode="Rrule">(0%)</td>
                                       <td>0</td>
                                       <td styleCode="Rrule">(0%)</td>
                                       <td>2</td>
                                       <td styleCode="Rrule">(1%)</td>
                                       <td>2</td>
                                       <td styleCode="Rrule">(1%)</td>
                                       <td>4</td>
                                       <td styleCode="Rrule">(3%)</td>
                                       <td>8</td>
                                       <td styleCode="Rrule">(2%)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <table width="100%" ID="table5">
                                 <caption>Table 5:  Other Common Adverse Reactions (≥2% for all doses of INTUNIV and &gt;rate than in placebo) in Fixed Dose Studies 1 and 2</caption>
                                 <col width="15%" align="left" valign="top"/>
                                 <col width="11%" align="center" valign="top"/>
                                 <col width="11%" align="center" valign="top"/>
                                 <col width="9%" align="center" valign="top"/>
                                 <col width="11%" align="center" valign="top"/>
                                 <col width="13%" align="center" valign="top"/>
                                 <col width="30%" align="center" valign="top"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule"/>
                                       <th styleCode="Rrule" colspan="5">INTUNIV (mg)</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Lrule Rrule" align="center">Adverse Reaction Term</th>
                                       <th styleCode="Rrule">Placebo<br/>(N=149)</th>
                                       <th styleCode="Rrule">1 mg<footnote ID="t5f1">The lowest dose of 1 mg used in Study 2 was not randomized to patients weighing more than 50 kg.</footnote>
                                          <br/>(N=61)</th>
                                       <th styleCode="Rrule">2 mg<br/>(N=150)</th>
                                       <th styleCode="Rrule">3 mg<br/>(N=151)</th>
                                       <th styleCode="Rrule">4 mg<br/>(N=151)</th>
                                       <th styleCode="Rrule">All Doses of INTUNIV (N=513)</th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td align="left" valign="top" colspan="7">Adverse reactions ≥2% for all doses of INTUNIV and &gt;rate in placebo in any dose group but did not meet this criteria in all doses combined: insomnia (insomnia, initial insomnia, middle insomnia, terminal insomnia, sleep disorder), vomiting, diarrhea, abdominal/stomach discomfort (abdominal discomfort, epigastric discomfort, stomach discomfort), rash (rash, rash generalized, rash papular), dyspepsia, increased weight, bradycardia (bradycardia, sinus bradycardia), asthma (asthma, bronchospasm, wheezing), agitation, anxiety (anxiety, nervousness), sinus arrhythmia, blood pressure increased (blood pressure increased, blood pressure diastolic increased), and first degree atrioventricular block.</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Headache</td>
                                       <td styleCode="Rrule">19%</td>
                                       <td styleCode="Rrule">26%</td>
                                       <td styleCode="Rrule">25%</td>
                                       <td styleCode="Rrule">16%</td>
                                       <td styleCode="Rrule">28%</td>
                                       <td styleCode="Rrule">23%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Abdominal Pain<footnote ID="t5fa">The abdominal pain term includes abdominal pain, abdominal pain lower, abdominal pain upper, and abdominal tenderness.</footnote>
                                       </td>
                                       <td styleCode="Rrule">9%</td>
                                       <td styleCode="Rrule">10%</td>
                                       <td styleCode="Rrule">7%</td>
                                       <td styleCode="Rrule">11%</td>
                                       <td styleCode="Rrule">15% </td>
                                       <td styleCode="Rrule">11% </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Decreased Appetite</td>
                                       <td styleCode="Rrule">4%</td>
                                       <td styleCode="Rrule">5%</td>
                                       <td styleCode="Rrule">4%</td>
                                       <td styleCode="Rrule">9%</td>
                                       <td styleCode="Rrule">6%</td>
                                       <td styleCode="Rrule">6%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Irritability</td>
                                       <td styleCode="Rrule">4%</td>
                                       <td styleCode="Rrule">5%</td>
                                       <td styleCode="Rrule">8%</td>
                                       <td styleCode="Rrule">3%</td>
                                       <td styleCode="Rrule">7%</td>
                                       <td styleCode="Rrule">6%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Constipation</td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">2%</td>
                                       <td styleCode="Rrule">2%</td>
                                       <td styleCode="Rrule">3%</td>
                                       <td styleCode="Rrule">4%</td>
                                       <td styleCode="Rrule">3%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Nightmare<footnote ID="t5fb">The nightmare term includes abnormal dreams, nightmare, and sleep terror.</footnote>
                                       </td>
                                       <td styleCode="Rrule">0%</td>
                                       <td styleCode="Rrule">0%</td>
                                       <td styleCode="Rrule">0%</td>
                                       <td styleCode="Rrule">3%</td>
                                       <td styleCode="Rrule">4%</td>
                                       <td styleCode="Rrule">2%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Enuresis<footnote ID="t5fc">The enuresis term includes enuresis, nocturia, and urinary incontinence.</footnote>
                                       </td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">0%</td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">3%</td>
                                       <td styleCode="Rrule">2%</td>
                                       <td styleCode="Rrule">2%</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Affect Lability<footnote ID="t5fd">The affect lability term includes affect lability and mood swings.</footnote>
                                       </td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">2%</td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">3%</td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">2%</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250408"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="f95f2979-788d-4cd1-b832-ed06806857ea"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Monotherapy Flexible Dose Trials</content>
                              </paragraph>
                              <table width="100%" ID="table6">
                                 <caption>Table 6:  Percentage of Patients Experiencing Most Common (≥5% and at least twice the rate for placebo) Adverse Reactions in the Monotherapy Flexible Dose Study 4</caption>
                                 <col width="40%" align="left" valign="top"/>
                                 <col width="15%" align="center" valign="top"/>
                                 <col width="15%" align="center" valign="top"/>
                                 <col width="15%" align="center" valign="top"/>
                                 <col width="15%" align="center" valign="top"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule"/>
                                       <th styleCode="Rrule" colspan="3">INTUNIV
													</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Lrule Rrule" align="center">Adverse Reaction Term</th>
                                       <th styleCode="Rrule">Placebo<br/>(N=112)</th>
                                       <th styleCode="Rrule">AM<br/>(N=107)</th>
                                       <th styleCode="Rrule">PM<br/>(N=114)</th>
                                       <th styleCode="Rrule">All Doses of INTUNIV (N=221)</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Somnolence<footnote ID="t6fa">The somnolence term includes somnolence, sedation, and hypersomnia.</footnote>
                                       </td>
                                       <td styleCode="Rrule">15%</td>
                                       <td styleCode="Rrule">57%</td>
                                       <td styleCode="Rrule">54%</td>
                                       <td styleCode="Rrule">56%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Abdominal Pain<footnote ID="t6fb">The abdominal pain term includes abdominal pain, abdominal pain lower, abdominal pain upper, and abdominal tenderness</footnote>
                                       </td>
                                       <td styleCode="Rrule">7%</td>
                                       <td styleCode="Rrule">8%</td>
                                       <td styleCode="Rrule">19%</td>
                                       <td styleCode="Rrule">14%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Fatigue</td>
                                       <td styleCode="Rrule">3%</td>
                                       <td styleCode="Rrule">10%</td>
                                       <td styleCode="Rrule">11%</td>
                                       <td styleCode="Rrule">11%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Irritability</td>
                                       <td styleCode="Rrule">3%</td>
                                       <td styleCode="Rrule">7%</td>
                                       <td styleCode="Rrule">7%</td>
                                       <td styleCode="Rrule">7%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Nausea</td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">6%</td>
                                       <td styleCode="Rrule">5%</td>
                                       <td styleCode="Rrule">5%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Dizziness</td>
                                       <td styleCode="Rrule">3%</td>
                                       <td styleCode="Rrule">6%</td>
                                       <td styleCode="Rrule">4%</td>
                                       <td styleCode="Rrule">5%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Vomiting</td>
                                       <td styleCode="Rrule">2%</td>
                                       <td styleCode="Rrule">7%</td>
                                       <td styleCode="Rrule">4%</td>
                                       <td styleCode="Rrule">5%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hypotension<footnote ID="t6fc">The hypotension term includes hypotension, diastolic hypotension, orthostatic hypotension, blood pressure decreased, blood pressure diastolic decreased, blood pressure systolic decreased).</footnote>
                                       </td>
                                       <td styleCode="Rrule">0%</td>
                                       <td styleCode="Rrule">6%</td>
                                       <td styleCode="Rrule">4%</td>
                                       <td styleCode="Rrule">5%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Decreased Appetite</td>
                                       <td styleCode="Rrule">3%</td>
                                       <td styleCode="Rrule">6%</td>
                                       <td styleCode="Rrule">3%</td>
                                       <td styleCode="Rrule">4%</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Enuresis<footnote ID="t6fd">The enuresis term includes enuresis, nocturia, and urinary incontinence.</footnote>
                                       </td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">2%</td>
                                       <td styleCode="Rrule">5%</td>
                                       <td styleCode="Rrule">4%</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <table width="100%" ID="table7">
                                 <caption>Table 7:  Adverse Reactions Leading to Discontinuation (≥2% for all doses of INTUNIV and &gt;rate than in placebo) in Monotherapy Flexible Dose Study 4</caption>
                                 <col width="22%" align="left" valign="top"/>
                                 <col width="9%" align="center" valign="top"/>
                                 <col width="9%" align="center" valign="top"/>
                                 <col width="9%" align="center" valign="top"/>
                                 <col width="9%" align="center" valign="top"/>
                                 <col width="9%" align="center" valign="top"/>
                                 <col width="9%" align="center" valign="top"/>
                                 <col width="12%" align="center" valign="top"/>
                                 <col width="12%" align="center" valign="top"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule" colspan="2"/>
                                       <th styleCode="Rrule" colspan="6">INTUNIV
													</th>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule" align="center">Adverse Reaction Term</th>
                                       <th styleCode="Rrule" colspan="2">Placebo<br/>(N=112)</th>
                                       <th styleCode="Rrule" colspan="2">AM<br/>(N=107)</th>
                                       <th styleCode="Rrule" colspan="2">PM<br/>(N=114)</th>
                                       <th styleCode="Rrule" colspan="2">All Doses of INTUNIV (N=221)</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Lrule Rrule"/>
                                       <th>n</th>
                                       <th styleCode="Rrule">(%)</th>
                                       <th>n</th>
                                       <th styleCode="Rrule">(%)</th>
                                       <th>n</th>
                                       <th styleCode="Rrule">(%)</th>
                                       <th>n</th>
                                       <th styleCode="Rrule">(%)</th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td align="left" valign="top" colspan="9">Adverse reactions leading to discontinuation in ≥2% in any dose group but did not meet this criteria in all doses combined: fatigue</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Total patients</td>
                                       <td>0</td>
                                       <td styleCode="Rrule">(0%)</td>
                                       <td>8</td>
                                       <td styleCode="Rrule">(7%)</td>
                                       <td>7</td>
                                       <td styleCode="Rrule">(6%)</td>
                                       <td>15</td>
                                       <td styleCode="Rrule">(7%)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Somnolence<footnote ID="t7fa">The somnolence term includes somnolence, sedation, and hypersomnia.</footnote>
                                       </td>
                                       <td>0</td>
                                       <td styleCode="Rrule">(0%)</td>
                                       <td>4</td>
                                       <td styleCode="Rrule">(4%)</td>
                                       <td>3</td>
                                       <td styleCode="Rrule">(3%)</td>
                                       <td>7</td>
                                       <td styleCode="Rrule">(3%)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <table width="100%" ID="table8">
                                 <caption>Table 8:  Other Common Adverse Reactions (≥2% for all doses of INTUNIV and &gt;rate than in placebo) in the Monotherapy Flexible Dose Study 4</caption>
                                 <col width="20%" align="left" valign="top"/>
                                 <col width="16%" align="center" valign="top"/>
                                 <col width="17%" align="center" valign="top"/>
                                 <col width="17%" align="center" valign="top"/>
                                 <col width="30%" align="center" valign="top"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule"/>
                                       <th styleCode="Rrule" colspan="3">INTUNIV
													</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Lrule Rrule" align="center">Adverse Reaction Term</th>
                                       <th styleCode="Rrule">Placebo<br/>(N=112)</th>
                                       <th styleCode="Rrule">AM<br/>(N=107)</th>
                                       <th styleCode="Rrule">PM<br/>(N=114)</th>
                                       <th styleCode="Rrule">All Doses of INTUNIV (N=221)</th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td align="left" valign="top" colspan="5">Adverse reactions ≥2% for all doses of INTUNIV and &gt;rate in placebo in any dose group but did not meet this criteria in all doses combined: affect lability (affect lability, mood swings), increased weight, syncope/loss of consciousness (loss of consciousness, presyncope, syncope), dyspepsia, tachycardia (tachycardia, sinus tachycardia), and bradycardia (bradycardia, sinus bradycardia).</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Headache</td>
                                       <td styleCode="Rrule">11%</td>
                                       <td styleCode="Rrule">18%</td>
                                       <td styleCode="Rrule">16%</td>
                                       <td styleCode="Rrule">17%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Insomnia<footnote ID="t8fa">The insomnia term includes insomnia, initial insomnia, middle insomnia, terminal insomnia, and sleep disorder.</footnote>
                                       </td>
                                       <td styleCode="Rrule">6%</td>
                                       <td styleCode="Rrule">8%</td>
                                       <td styleCode="Rrule">6%</td>
                                       <td styleCode="Rrule">7%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Diarrhea</td>
                                       <td styleCode="Rrule">4%</td>
                                       <td styleCode="Rrule">4%</td>
                                       <td styleCode="Rrule">6%</td>
                                       <td styleCode="Rrule">5%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Lethargy</td>
                                       <td styleCode="Rrule">0%</td>
                                       <td styleCode="Rrule">4%</td>
                                       <td styleCode="Rrule">3%</td>
                                       <td styleCode="Rrule">3%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Constipation</td>
                                       <td styleCode="Rrule">2%</td>
                                       <td styleCode="Rrule">2%</td>
                                       <td styleCode="Rrule">4%</td>
                                       <td styleCode="Rrule">3%</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Dry Mouth</td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">3%</td>
                                       <td styleCode="Rrule">3%</td>
                                       <td styleCode="Rrule">3%</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <table width="100%" ID="table9">
                                 <caption>Table 9:  Percentage of Patients Experiencing Most Common (≥5% and at least twice the rate for placebo) Adverse Reactions in the Monotherapy Flexible Dose Study 5</caption>
                                 <col width="33%" align="left" valign="top"/>
                                 <col width="33%" align="center" valign="top"/>
                                 <col width="34%" align="center" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule" align="center">Adverse Reaction Term</th>
                                       <th styleCode="Rrule">Placebo<br/>(N=155)</th>
                                       <th styleCode="Rrule">All Doses of INTUNIV (N=157)</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Somnolence<footnote ID="t9fa">The somnolence term includes somnolence, sedation, and hypersomnia.</footnote>
                                       </td>
                                       <td styleCode="Rrule">23%</td>
                                       <td styleCode="Rrule">54%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Insomnia<footnote ID="t9fb">The insomnia term includes insomnia, initial insomnia, middle insomnia, terminal insomnia, and sleep disorder.</footnote>
                                       </td>
                                       <td styleCode="Rrule">6%</td>
                                       <td styleCode="Rrule">13%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hypotension<footnote ID="t9fc">The hypotension term includes hypotension, diastolic hypotension, orthostatic hypotension, blood pressure decreased, blood pressure diastolic decreased, blood pressure systolic decreased).</footnote>
                                       </td>
                                       <td styleCode="Rrule">3%</td>
                                       <td styleCode="Rrule">9%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Dry Mouth</td>
                                       <td styleCode="Rrule">0%</td>
                                       <td styleCode="Rrule">8%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Postural Dizziness</td>
                                       <td styleCode="Rrule">2%</td>
                                       <td styleCode="Rrule">5%</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Bradycardia<footnote ID="t9fd">The bradycardia term includes bradycardia and sinus bradycardia.</footnote>
                                       </td>
                                       <td styleCode="Rrule">0%</td>
                                       <td styleCode="Rrule">5%</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>There were no specific adverse reactions ≥2% in any treatment group that led to discontinuation in the monotherapy flexible dose study (Study 5).</paragraph>
                              <table width="100%" ID="table10">
                                 <caption>Table 10:  Other Common Adverse Reactions (≥2% for all doses of INTUNIV and &gt;rate than in placebo) in the Monotherapy Flexible Dose Study 5</caption>
                                 <col width="25%" align="left" valign="top"/>
                                 <col width="35%" align="center" valign="top"/>
                                 <col width="40%" align="center" valign="top"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule"/>
                                       <th styleCode="Rrule">INTUNIV
													</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Lrule Rrule" align="center">Adverse Reaction Term</th>
                                       <th styleCode="Rrule">Placebo<br/>(N=155)</th>
                                       <th styleCode="Rrule">All Doses of INTUNIV (N=157)</th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td align="left" valign="top" colspan="3">Adverse reactions ≥2% for all doses of INTUNIV and &gt;rate in placebo in any dose group but did not meet this criteria in all doses combined: nausea, diarrhea, vomiting, and depression (depressed mood, depression, depressive symptom).</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Headache</td>
                                       <td styleCode="Rrule">18%</td>
                                       <td styleCode="Rrule">27%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Fatigue</td>
                                       <td styleCode="Rrule">12%</td>
                                       <td styleCode="Rrule">22%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Dizziness</td>
                                       <td styleCode="Rrule">10%</td>
                                       <td styleCode="Rrule">16%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Decreased Appetite</td>
                                       <td styleCode="Rrule">14%</td>
                                       <td styleCode="Rrule">15%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Abdominal Pain<footnote ID="t10fa">The abdominal pain term includes abdominal pain, abdominal pain lower, abdominal pain upper, and abdominal tenderness.</footnote>
                                       </td>
                                       <td styleCode="Rrule">8%</td>
                                       <td styleCode="Rrule">12%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Irritability</td>
                                       <td styleCode="Rrule">4%</td>
                                       <td styleCode="Rrule">7%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Anxiety<footnote ID="t10fb">The anxiety term includes anxiety and nervousness.</footnote>
                                       </td>
                                       <td styleCode="Rrule">3%</td>
                                       <td styleCode="Rrule">5%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Rash<footnote ID="t10fc">The rash term includes rash, rash generalized, and rash papular.</footnote>
                                       </td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">3%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Constipation</td>
                                       <td styleCode="Rrule">0%</td>
                                       <td styleCode="Rrule">3%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Increased Weight</td>
                                       <td styleCode="Rrule">2%</td>
                                       <td styleCode="Rrule">3%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Abdominal/Stomach Discomfort<footnote ID="t10fd">The abdominal/stomach discomfort term includes abdominal discomfort, epigastric discomfort, and stomach discomfort.</footnote>
                                       </td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">2%</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Pruritus</td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">2%</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250408"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="d2deeccd-cd75-4472-b837-cbb271c34442"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adjunctive Trial</content>
                              </paragraph>
                              <table width="100%" ID="table11">
                                 <caption>Table 11:  Percentage of Patients Experiencing Most Common (≥5% and at least twice the rate for placebo) Adverse Reactions in the Short-Term Adjunctive Study 3</caption>
                                 <col width="22%" align="left" valign="top"/>
                                 <col width="19%" align="center" valign="top"/>
                                 <col width="19%" align="center" valign="top"/>
                                 <col width="19%" align="center" valign="top"/>
                                 <col width="21%" align="center" valign="top"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule"/>
                                       <th styleCode="Rrule" colspan="3">INTUNIV + stimulant</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Lrule Rrule" align="center">Adverse Reaction Term</th>
                                       <th styleCode="Rrule">Placebo+ stimulant<br/>(N=153)</th>
                                       <th styleCode="Rrule">AM<br/>(N=150)</th>
                                       <th styleCode="Rrule">PM<br/>(N=152)</th>
                                       <th styleCode="Rrule">All Doses (N=302)</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Somnolence<footnote ID="t11fa">The somnolence term includes somnolence, sedation, and hypersomnia.</footnote>
                                       </td>
                                       <td styleCode="Rrule">7%</td>
                                       <td styleCode="Rrule">18%</td>
                                       <td styleCode="Rrule">18%</td>
                                       <td styleCode="Rrule">18%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Insomnia<footnote ID="t11fb">The insomnia term includes insomnia, initial insomnia, middle insomnia, terminal insomnia, and sleep disorder.</footnote>
                                       </td>
                                       <td styleCode="Rrule">6%</td>
                                       <td styleCode="Rrule">10%</td>
                                       <td styleCode="Rrule">14%</td>
                                       <td styleCode="Rrule">12%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Abdominal Pain<footnote ID="t11fc">The abdominal pain term includes abdominal pain, abdominal pain lower, abdominal pain upper, and abdominal tenderness.</footnote>
                                       </td>
                                       <td styleCode="Rrule">3%</td>
                                       <td styleCode="Rrule">8%</td>
                                       <td styleCode="Rrule">12%</td>
                                       <td styleCode="Rrule">10%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Fatigue</td>
                                       <td styleCode="Rrule">3%</td>
                                       <td styleCode="Rrule">12%</td>
                                       <td styleCode="Rrule">7%</td>
                                       <td styleCode="Rrule">10%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Dizziness</td>
                                       <td styleCode="Rrule">4%</td>
                                       <td styleCode="Rrule">10%</td>
                                       <td styleCode="Rrule">5%</td>
                                       <td styleCode="Rrule">8%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Decreased Appetite</td>
                                       <td styleCode="Rrule">4%</td>
                                       <td styleCode="Rrule">7%</td>
                                       <td styleCode="Rrule">8%</td>
                                       <td styleCode="Rrule">7%</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Nausea</td>
                                       <td styleCode="Rrule">3%</td>
                                       <td styleCode="Rrule">3%</td>
                                       <td styleCode="Rrule">7%</td>
                                       <td styleCode="Rrule">5%</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>There were no specific adverse reactions ≥2% in any treatment group that led to discontinuation in the short-term adjunctive study (Study 3).</paragraph>
                              <table width="100%" ID="table12">
                                 <caption>Table 12:  Other Common Adverse Reactions (≥2% for all doses of INTUNIV and &gt;rate than in placebo) in the Short-Term Adjunctive Study 3</caption>
                                 <col width="15%" align="left" valign="top"/>
                                 <col width="15%" align="center" valign="top"/>
                                 <col width="20%" align="center" valign="top"/>
                                 <col width="20%" align="center" valign="top"/>
                                 <col width="30%" align="center" valign="top"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule"/>
                                       <th styleCode="Rrule" colspan="3">INTUNIV + stimulant</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Lrule Rrule" align="center">Adverse Reaction Term</th>
                                       <th styleCode="Rrule">Placebo<br/>(N=153)</th>
                                       <th styleCode="Rrule">AM<br/>(N=150)</th>
                                       <th styleCode="Rrule">PM<br/>(N=152)</th>
                                       <th styleCode="Rrule">All Doses of INTUNIV (N=302)</th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td align="left" valign="top" colspan="5">Adverse reactions ≥2% for all doses of INTUNIV and &gt;rate in placebo in any dose group but did not meet this criteria in all doses combined: irritability, vomiting, asthma (asthma, bronchospasm, wheezing), and enuresis (enuresis, nocturia, urinary incontinence).</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Headache</td>
                                       <td styleCode="Rrule">13%</td>
                                       <td styleCode="Rrule">21%</td>
                                       <td styleCode="Rrule">21%</td>
                                       <td styleCode="Rrule">21%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Diarrhea</td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">4%</td>
                                       <td styleCode="Rrule">3%</td>
                                       <td styleCode="Rrule">4%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hypotension<footnote ID="t12fa">The hypotension term includes hypotension, diastolic hypotension, orthostatic hypotension, blood pressure decreased, blood pressure diastolic decreased, blood pressure systolic decreased.</footnote>
                                       </td>
                                       <td styleCode="Rrule">0%</td>
                                       <td styleCode="Rrule">4%</td>
                                       <td styleCode="Rrule">2%</td>
                                       <td styleCode="Rrule">3%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Constipation</td>
                                       <td styleCode="Rrule">0%</td>
                                       <td styleCode="Rrule">2%</td>
                                       <td styleCode="Rrule">3%</td>
                                       <td styleCode="Rrule">2%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Affect Lability<footnote ID="t12fb">The affect lability term includes affect lability and mood swings.</footnote>
                                       </td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">3%</td>
                                       <td styleCode="Rrule">2%</td>
                                       <td styleCode="Rrule">2%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Dry Mouth</td>
                                       <td styleCode="Rrule">0%</td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">3%</td>
                                       <td styleCode="Rrule">2%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Bradycardia<footnote ID="t12fc">The bradycardia term includes bradycardia and sinus bradycardia.</footnote>
                                       </td>
                                       <td styleCode="Rrule">0%</td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">3%</td>
                                       <td styleCode="Rrule">2%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Postural Dizziness</td>
                                       <td styleCode="Rrule">0%</td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">3%</td>
                                       <td styleCode="Rrule">2%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Rash<footnote ID="t12fd">The rash term includes rash, rash generalized, and rash papular.</footnote>
                                       </td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">2%</td>
                                       <td styleCode="Rrule">2%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Nightmare<footnote ID="t12fe">The nightmare term includes abnormal dreams, nightmare, and sleep terror.</footnote>
                                       </td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">2%</td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">2%</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Tachycardia<footnote ID="f12ff">The tachycardia term includes tachycardia and sinus tachycardia.</footnote>
                                       </td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">2%</td>
                                       <td styleCode="Rrule">1%</td>
                                       <td styleCode="Rrule">2%</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250408"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="804da3ef-2ea2-4485-84be-d6197041a988"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Effects on Blood Pressure and Heart Rate </content>
                              </paragraph>
                              <paragraph>In the monotherapy pediatric, short-term, controlled trials (Studies 1 and 2), the maximum mean changes from baseline in seated systolic blood pressure, diastolic blood pressure, and pulse were −5.4 mmHg, −3.4 mmHg, and −5.5 bpm, respectively, for all doses combined (generally one week after reaching target doses). For the respective fixed doses 1 mg/day, 2 mg/day, 3 mg/day, or 4 mg/day the maximum mean changes in seated systolic blood pressure were -4.3 mmHg, -5.5 mmHg, -5.4 mmHg, and -8.2 mmHg. For these respective fixed doses the maximum mean changes in seated diastolic blood pressure were -3.4 mmHg, -3.3 mmHg, -4.4 mmHg, and -5.4 mmHg. For these respective fixed doses the maximum mean changes in seated pulse were -4.8 bpm, -3.1 bpm, -6.5 bpm, and -8.6 bpm. Decreases in blood pressure and heart rate were usually modest and asymptomatic; however, hypotension and bradycardia can occur. Hypotension was reported as an adverse reaction for 7% of the INTUNIV group and 3% of the placebo group. This includes orthostatic hypotension, which was reported for 1% of the INTUNIV group and none in the placebo group. These findings were generally similar in the monotherapy flexible dose trials (Studies 4 and 5). In the adjunctive trial, hypotension (3%) and bradycardia (2%) were observed in patients treated with INTUNIV as compared to none in the placebo group. In long-term, open-label studies, (mean exposure of approximately 10 months), maximum decreases in systolic and diastolic blood pressure occurred in the first month of therapy. Decreases were less pronounced over time. Syncope occurred in 1% of pediatric patients in the clinical program. The majority of these cases occurred in the long-term, open-label studies.</paragraph>
                           </text>
                           <effectiveTime value="20250408"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="9abcbc8f-af55-4c5e-b0f3-059d0a16aee6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Discontinuation of Treatment</content>
                              </paragraph>
                              <paragraph>Blood pressure and pulse may increase above baseline values following discontinuation of INTUNIV. In five studies of children and adolescents <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>, increases in mean systolic and diastolic blood pressure averaging approximately 3 mmHg and increases in heart rate averaging 5 beats per minute above original baseline were observed upon discontinuation with tapering of INTUNIV. In a maintenance of efficacy study, increases in blood pressure and heart rate above baseline slowly diminished over the follow up period, which ranged between 3 and 26 weeks post final dose; the estimated average time to return to baseline was between six and twelve months. In this study, the increases in blood pressure and pulse were not considered serious or associated with adverse events. However, individuals may have larger increases than reflected by the mean changes.</paragraph>
                              <paragraph>In postmarketing experience, following abrupt discontinuation of INTUNIV, rebound hypertension and hypertensive encephalopathy have been reported <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml> and <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20250408"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="95f6bc63-182e-41d0-aaf0-15fc98391930"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Effects on Height, Weight, and Body Mass Index (BMI)</content>
                              </paragraph>
                              <paragraph>Patients taking INTUNIV demonstrated similar growth compared to normative data. Patients taking INTUNIV had a mean increase in weight of 0.5 kg compared to those receiving placebo over a comparable treatment period. Patients receiving INTUNIV for at least 12 months in open-label studies gained an average of 8 kg in weight and 8 cm (3 in) in height. The height, weight, and BMI percentile remained stable in patients at 12 months in the long-term studies compared to when they began receiving INTUNIV.</paragraph>
                           </text>
                           <effectiveTime value="20250408"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="8a95a69a-606d-4325-86f4-c24674f6c0e1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Other Adverse Reactions Observed in Clinical Studies</content>
                              </paragraph>
                              <paragraph>Table 13 includes additional adverse reactions observed in short-term, placebo-controlled and long-term, open-label clinical studies not included elsewhere in section 6.1, listed by organ system.</paragraph>
                              <table width="75%" ID="table13">
                                 <caption>Table 13: Other adverse reactions observed in clinical studies</caption>
                                 <col width="25%" align="left" valign="top"/>
                                 <col width="75%" align="left" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule">Body System</th>
                                       <th styleCode="Rrule">Adverse Reaction</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Cardiac</td>
                                       <td styleCode="Rrule">Atrioventricular block</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">General</td>
                                       <td styleCode="Rrule">Asthenia, chest pain</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Immune System Disorders</td>
                                       <td styleCode="Rrule">Hypersensitivity</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Investigations</td>
                                       <td styleCode="Rrule">Increased alanine amino transferase</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Nervous system</td>
                                       <td styleCode="Rrule">Convulsion</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Renal</td>
                                       <td styleCode="Rrule">Increased urinary frequency</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Vascular</td>
                                       <td styleCode="Rrule">Hypertension, pallor</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250408"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S6.2">
                     <id root="ba8fdef2-7d12-435d-b692-5c4cfc3af93c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of guanfacine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>Less frequent, possibly guanfacine-related events observed in the post-marketing study and/or reported spontaneously, not included in section 6.1, include:</paragraph>
                        <paragraph>
                           <content styleCode="bold italics">General: </content>edema, malaise, tremor</paragraph>
                        <paragraph>
                           <content styleCode="bold italics">Cardiovascular: </content>palpitations, tachycardia, rebound hypertension, hypertensive encephalopathy</paragraph>
                        <paragraph>
                           <content styleCode="bold italics">Central Nervous System: </content>paresthesias, vertigo</paragraph>
                        <paragraph>
                           <content styleCode="bold italics">Eye Disorders: </content>blurred vision</paragraph>
                        <paragraph>
                           <content styleCode="bold italics">Musculo-Skeletal System: </content>arthralgia, leg cramps, leg pain, myalgia</paragraph>
                        <paragraph>
                           <content styleCode="bold italics">Psychiatric: </content>confusion, hallucinations</paragraph>
                        <paragraph>
                           <content styleCode="bold italics">Reproductive System, Male: </content>erectile dysfunction</paragraph>
                        <paragraph>
                           <content styleCode="bold italics">Respiratory System: </content>dyspnea</paragraph>
                        <paragraph>
                           <content styleCode="bold italics">Skin and Appendages: </content>alopecia, dermatitis, exfoliative dermatitis, pruritus, rash</paragraph>
                        <paragraph>
                           <content styleCode="bold italics">Special Senses: </content>alterations in taste</paragraph>
                     </text>
                     <effectiveTime value="20250408"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="3f00f8ee-4cbe-421e-8224-43c90f538f9f"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph>Table 14 contains clinically important drug interactions with INTUNIV
							<content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                  </paragraph>
                  <table width="75%" ID="table14">
                     <caption>Table 14: Clinically Important Drug Interactions: Effect of other Drugs on INTUNIV
							</caption>
                     <col width="34%" align="left" valign="top"/>
                     <col width="33%" align="left" valign="top"/>
                     <col width="33%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td styleCode="Lrule Rrule Botrule">Concomitant Drug Name or Drug Class</td>
                           <td styleCode="Rrule Botrule">Clinical Rationale and Magnitude of Drug Interaction</td>
                           <td styleCode="Rrule Botrule">Clinical Recommendation</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">Strong and moderate CYP3A4 inhibitors, e.g., ketoconazole, fluconazole</td>
                           <td styleCode="Rrule">Guanfacine is primarily metabolized by CYP3A4 and its plasma concentrations can be significantly affected resulting in an increase in exposure</td>
                           <td styleCode="Rrule">Consider dose reduction <content styleCode="italics">[see <linkHtml href="#S2.7">Dosage and administration (2.7)</linkHtml>]</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule">Strong and moderate CYP3A4 inducers, e.g., rifampin, efavirenz</td>
                           <td styleCode="Rrule">Guanfacine is primarily metabolized by CYP3A4 and its plasma concentrations can be significantly affected resulting in a decrease in exposure</td>
                           <td styleCode="Rrule">Consider dose increase <content styleCode="italics">[see <linkHtml href="#S2.7">Dosage and administration (2.7)</linkHtml>]</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250408"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item> Strong and moderate CYP3A4 inhibitors increase guanfacine exposure. Decrease INTUNIV<content styleCode="bold"/> to 50% of target dosage when coadministered with strong and moderate CYP3A4 inhibitors (<linkHtml href="#S2.7">2.7</linkHtml>).</item>
                           <item> Strong and moderate CYP3A4 inducers decrease guanfacine exposure. Based on patient response, consider titrating INTUNIV dosage up to double the target dosage over 1 to 2 weeks (<linkHtml href="#S2.7">2.7</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="0825d4a2-cc28-46b9-bc82-b5780310ce16"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8	USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250408"/>
               <component>
                  <section ID="S8.1">
                     <id root="3d68e399-ebd1-4625-b073-262b96ca9c02"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20250408"/>
                     <component>
                        <section>
                           <id root="9d59dc9c-b588-4841-8cc6-6ee69583bade"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>Pregnancy Exposure Registry </paragraph>
                              <paragraph>There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ADHD medications, including INTUNIV, during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for ADHD Medications at 1-866-961-2388.</paragraph>
                           </text>
                           <effectiveTime value="20250408"/>
                           <component>
                              <section>
                                 <id root="85d6d03e-6c2b-4871-abe8-a426c88ce656"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline">Risk Summary</content>
                                    </paragraph>
                                    <paragraph>Available data with guanfacine over decades of use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. However, use of guanfacine in pregnant women over this time has been infrequent. In animal reproduction studies, rabbits and rats exposed to 3 and 4 times the maximum recommended human dose (MRHD), respectively, showed no adverse outcomes. However, higher doses were associated with reduced fetal survival and maternal toxicity (<content styleCode="italics">see <linkHtml href="#Data1">Data</linkHtml>
                                       </content>).</paragraph>
                                    <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated risk of major birth defects and miscarriage in <content styleCode="underline">clinically</content> recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                                 </text>
                                 <effectiveTime value="20250408"/>
                              </section>
                           </component>
                           <component>
                              <section ID="Data1">
                                 <id root="02bb48c8-ff72-426f-8fbc-599eb8219f14"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline">Data</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250408"/>
                                 <component>
                                    <section>
                                       <id root="d7c0b05e-ce04-441e-b3e2-f5e8b302f4da"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Animal Data</content>
                                          </paragraph>
                                          <paragraph>Reproduction studies conducted in rats have shown that guanfacine crosses the placenta. However, administration of guanfacine to rabbits and rats during organogenesis at 3 (rabbit) and 4 (rat) times the MRHD of 0.12 mg/kg/day on a mg/m<sup>2</sup> basis resulted in no evidence of harm to the fetus. Higher doses (13.5 times the MRHD in both rabbits and rats) were associated with reduced fetal survival and maternal toxicity.</paragraph>
                                       </text>
                                       <effectiveTime value="20250408"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="fd2bee85-02dc-4c61-854e-7126178a91cc"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20250408"/>
                     <component>
                        <section>
                           <id root="225046ae-fa06-4891-b4c3-4eec5f228128"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no data on the presence of guanfacine in human milk or the effects on the breastfed infant. The effects on milk production are also unknown. Guanfacine is present in the milk of lactating rats <content styleCode="italics">(see <linkHtml href="#Data2">Data</linkHtml>)</content>. If a drug is present in animal milk, it is likely that the drug will be present in human milk. If an infant is exposed to guanfacine through breastmilk, monitor for symptoms of hypotension and bradycardia such as sedation, lethargy, and poor feeding <content styleCode="italics">(see <linkHtml href="#CC">Clinical Considerations</linkHtml>).</content> The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for INTUNIV and any potential adverse effects on the breastfed child from INTUNIV or from the underlying maternal condition.</paragraph>
                           </text>
                           <effectiveTime value="20250408"/>
                        </section>
                     </component>
                     <component>
                        <section ID="CC">
                           <id root="1a397551-03c5-4407-b0e8-f095124f6993"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                              <paragraph>Monitor breastfeeding infants exposed to guanfacine through breastmilk for sedation, lethargy, and poor feeding.</paragraph>
                           </text>
                           <effectiveTime value="20250408"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Data2">
                           <id root="ed001c34-2da6-47e5-a1d8-c3af8fb35897"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                              <paragraph>Guanfacine was excreted in breast milk of lactating rats at a concentration comparable to that observed in blood, but slightly less than the concentration in plasma when administered following a single oral dose of 5 mg/kg. The concentration of drug in animal milk does not necessarily predict the concentration of drug in human milk.</paragraph>
                           </text>
                           <effectiveTime value="20250408"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="a15678a5-18c2-41e3-a233-c6d93993d6fd"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and efficacy of INTUNIV in pediatric patients less than 6 years of age have not been established. The efficacy of INTUNIV was studied for the treatment of ADHD in five controlled monotherapy clinical trials (up to 15 weeks in duration), one randomized withdrawal study and one controlled adjunctive trial with psychostimulants (8 weeks in duration) in children and adolescents ages 6 to 17 who met DSM-IV<sup>®</sup> criteria for ADHD <content styleCode="italics">[see <linkHtml href="#S6">Adverse Reactions (6)</linkHtml> and <linkHtml href="#S14">Clinical Studies (14)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250408"/>
                     <component>
                        <section>
                           <id root="724d6aa5-a051-4a8a-aa9d-b7b11cffaf09"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Animal Data</content>
                              </paragraph>
                              <paragraph>In studies in juvenile rats, guanfacine alone produced a slight delay in sexual maturation in males and females at 2 to 3 times the maximum recommended human dose (MRHD). Guanfacine in combination with methylphenidate produced a slight delay in sexual maturation and decreased growth as measured by a decrease in bone length in males at a dose of guanfacine comparable to the MRHD and a dose of methylphenidate approximately 4 times the MRHD.</paragraph>
                              <paragraph>In a study where juvenile rats were treated with guanfacine alone from 7 to 59 days of age, development was delayed as indicated by a slight delay in sexual maturation and decreased body weight gain in males at 2 mg/kg/day and in females at 3 mg/kg/day. The No Adverse Effect Level (NOAEL) for delayed sexual maturation was 1 mg/kg/day, which is equivalent to the MRHD of 4 mg/day, on a mg/m<sup>2</sup> basis. The effects on fertility were not evaluated in this study.</paragraph>
                              <paragraph>In a study where juvenile rats were treated with guanfacine in combination with methylphenidate from 7 to 59 days of age, a decrease in ulna bone length and a slight delay in sexual maturation were observed in males given 1 mg/kg/day of guanfacine in combination with 50 mg/kg/day of methylphenidate. The NOAELs for these findings were 0.3 mg/kg of guanfacine in combination with 16 mg/kg/day of methylphenidate, which are equivalent to 0.3 and 1.4 times the MRHD of 4 mg/day and 54 mg/day for guanfacine and methylphenidate, respectively, on a mg/m<sup>2</sup> basis. These findings were not observed with guanfacine alone at 1 mg/kg/day or methylphenidate alone at 50 mg/kg/day.</paragraph>
                           </text>
                           <effectiveTime value="20250408"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="0888abfd-5bff-421b-a26b-455854373edc"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5	Geriatric Use</title>
                     <text>
                        <paragraph>The safety and efficacy of INTUNIV in geriatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250408"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="6895ddea-d4e7-486d-930f-8267cf42f5c3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6	Renal Impairment</title>
                     <text>
                        <paragraph>It may be necessary to reduce the dosage in patients with significant impairment of renal function <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250408"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.7">
                     <id root="baf701fe-a651-403d-8761-58cbabce5878"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.7	Hepatic Impairment</title>
                     <text>
                        <paragraph>It may be necessary to reduce the dosage in patients with significant impairment of hepatic function <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250408"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S9">
               <id root="ac9f6328-d70c-41a3-bd70-800578e45100"/>
               <code code="42227-9" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG ABUSE AND DEPENDENCE SECTION"/>
               <title>9	DRUG ABUSE AND DEPENDENCE</title>
               <effectiveTime value="20250408"/>
               <component>
                  <section ID="S9.1">
                     <id root="7a25989e-a9e1-43bf-bdfa-5b538879aece"/>
                     <code code="34085-1" codeSystem="2.16.840.1.113883.6.1" displayName="CONTROLLED SUBSTANCE SECTION"/>
                     <title>9.1 Controlled Substance</title>
                     <text>
                        <paragraph>INTUNIV is not a controlled substance and has no known potential for abuse or dependence.</paragraph>
                     </text>
                     <effectiveTime value="20250408"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="531295fb-172b-4de8-a384-fd16e837f061"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <effectiveTime value="20250408"/>
               <component>
                  <section>
                     <id root="792a16f6-ed3c-4a3b-bcb3-2406620712d5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Symptoms</content>
                        </paragraph>
                        <paragraph>Postmarketing reports of guanfacine overdosage indicate that hypotension, drowsiness, lethargy, and bradycardia have been observed following overdose. Initial hypertension may develop early and may be followed by hypotension. Similar symptoms have been described in voluntary reports to the American Association of Poison Control Center's National Poison Data System. Miosis of the pupils may be noted on examination<content styleCode="bold">.</content> No fatal overdoses of guanfacine have been reported in published literature.</paragraph>
                     </text>
                     <effectiveTime value="20250408"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="ccb43ee4-dd24-46c6-8416-1320272e6eb3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Treatment</content>
                        </paragraph>
                        <paragraph>Consult a Certified Poison Control Center by calling 1-800-222-1222 for up-to-date guidance and advice.</paragraph>
                        <paragraph>Management of INTUNIV overdose should include monitoring for and the treatment of initial hypertension, if that occurs, as well as hypotension, bradycardia, lethargy, and respiratory depression. Children and adolescents who develop lethargy should be observed for the development of more serious toxicity including coma, bradycardia, and hypotension for up to 24 hours, due to the possibility of delayed onset hypotension.</paragraph>
                     </text>
                     <effectiveTime value="20250408"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="fd8312b8-35d5-43cf-b067-e0a570b28a3d"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>INTUNIV is a once-daily, extended-release formulation of guanfacine hydrochloride (HCl) in a matrix tablet formulation for oral administration only. The chemical designation is N-amidino-2-(2,6-dichlorophenyl) acetamide monohydrochloride. The molecular formula is C<sub>9</sub>H<sub>9</sub>Cl<sub>2</sub> N<sub>3</sub>O∙HCl corresponding to a molecular weight of 282.55 g/mol. The chemical structure is:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>Guanfacine HCl is a white to off-white crystalline powder, sparingly soluble in water (approximately 1 mg/mL) and alcohol and slightly soluble in acetone. The only organic solvent in which it has relatively high solubility is methanol (&gt;30 mg/mL). Each tablet contains guanfacine HCl equivalent to 1 mg, 2 mg, 3 mg, or 4 mg of guanfacine base. The tablets also contain hypromellose, methacrylic acid copolymer, lactose, povidone, crospovidone, microcrystalline cellulose, fumaric acid, and glyceryl behenate. In addition, the 3-mg and 4-mg tablets also contain green pigment blend PB-1763.</paragraph>
               </text>
               <effectiveTime value="20250408"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Stucture</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="intuniv-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="0b0c1fb5-18a5-4666-863b-3932b3ca5cb0"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12	CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250408"/>
               <component>
                  <section ID="S12.1">
                     <id root="8c43b417-3fe8-458d-ad9b-3692809cc891"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Guanfacine is a central alpha<sub>2A</sub>-adrenergic receptor agonist. Guanfacine is not a central nervous system (CNS) stimulant. The mechanism of action of guanfacine in ADHD is not known.</paragraph>
                     </text>
                     <effectiveTime value="20250408"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="48232350-4bac-4f51-a7bd-27e9a1bfe721"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Guanfacine is a selective central alpha<sub>2A</sub>-adrenergic receptor agonist in that it has a 15 to 20 times higher affinity for this receptor subtype than for the alpha<sub>2B</sub> or alpha<sub>2C</sub> subtypes.</paragraph>
                        <paragraph>Guanfacine is a known antihypertensive agent. By stimulating central alpha<sub>2A</sub>-adrenergic receptors, guanfacine reduces sympathetic nerve impulses from the vasomotor center to the heart and blood vessels. This results in a decrease in peripheral vascular resistance and a reduction in heart rate.</paragraph>
                        <paragraph>In a thorough QT study, the administration of two dose levels of immediate-release guanfacine (4 mg and 8 mg) produced concentrations approximately 2 to 4 times the concentrations observed with the maximum recommended dose of INTUNIV of 0.12 mg/kg. Guanfacine was not shown to prolong the QTc interval to any clinically relevant extent.</paragraph>
                     </text>
                     <effectiveTime value="20250408"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="87e18f76-a831-4148-a153-3c5c65cb5669"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <effectiveTime value="20250408"/>
                     <component>
                        <section>
                           <id root="23dc685b-eb13-4178-90af-27b95df5bda0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption and Distribution</content>
                              </paragraph>
                              <paragraph>Guanfacine is readily absorbed and approximately 70% bound to plasma proteins independent of drug concentration. After oral administration of INTUNIV the time to peak plasma concentration is approximately 5 hours in children and adolescents with ADHD.</paragraph>
                              <paragraph>Immediate-release guanfacine and INTUNIV have different pharmacokinetic characteristics; dose substitution on a milligram per milligram basis will result in differences in exposure.</paragraph>
                              <paragraph>A comparison across studies suggests that the C<sub>max</sub> is 60% lower and AUC<sub>0-∞ </sub>43% lower, respectively, for INTUNIV compared to immediate-release guanfacine. Therefore, the relative bioavailability of INTUNIV to immediate-release guanfacine is 58%. The mean pharmacokinetic parameters in adults following the administration of INTUNIV 1 mg once daily and immediate-release guanfacine 1 mg once daily are summarized in Table 15.</paragraph>
                              <table width="75%" ID="table15">
                                 <caption>Table 15: Comparison of Pharmacokinetics: INTUNIV vs. Immediate release Guanfacine in Adults</caption>
                                 <col width="25%" align="left" valign="top"/>
                                 <col width="30%" align="center" valign="top"/>
                                 <col width="45%" align="center" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule">Parameter</th>
                                       <th styleCode="Rrule">INTUNIV 1 mg once daily<br/>(n=52)</th>
                                       <th styleCode="Rrule">Immediate-release guanfacine 1 mg once daily<br/>(n=12)</th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td align="left" valign="top" colspan="3">Note: Values are mean +/- SD, except for t<sub>max</sub> which is median (range)</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">C<sub>max</sub> (ng/mL)</td>
                                       <td styleCode="Rrule">1.0 ± 0.3</td>
                                       <td styleCode="Rrule">2.5 ± 0.6</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">AUC<sub>0-∞</sub> (ng∙h/mL)</td>
                                       <td styleCode="Rrule">32 ± 9</td>
                                       <td styleCode="Rrule">56 ± 15</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">t<sub>max</sub> (h)</td>
                                       <td styleCode="Rrule">6.0 (4.0 – 8.0)</td>
                                       <td styleCode="Rrule">3.0 (1.5-4.0)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">t<sub>½</sub> (h)</td>
                                       <td styleCode="Rrule">18 ± 4</td>
                                       <td styleCode="Rrule">16 ± 3</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>
                                 <content styleCode="bold">Figure 1: Comparison of Pharmacokinetics: INTUNIV vs. Immediate-release guanfacine in Adults</content>
                              </paragraph>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM2"/>
                              </paragraph>
                              <paragraph>Exposure to guanfacine was higher in children (ages 6 to 12) compared to adolescents (ages 13 to 17) and adults. After oral administration of multiple doses of INTUNIV 4 mg, the C<sub>max</sub> was 10 ng/mL compared to 7 ng/mL and the AUC was 162 ng∙h/mL compared to 116 ng∙h/mL in children (ages 6 to 12) and adolescents (ages 13 to 17), respectively. These differences are probably attributable to the lower body weight of children compared to adolescents and adults.</paragraph>
                              <paragraph>The pharmacokinetics were affected by intake of food when a single dose of INTUNIV 4 mg was administered with a high-fat breakfast. The mean exposure increased (C<sub>max</sub> ~75% and AUC ~40%) compared to dosing in a fasted state.</paragraph>
                           </text>
                           <effectiveTime value="20250408"/>
                           <component>
                              <observationMedia ID="MM2">
                                 <text>Figure 1</text>
                                 <value xsi:type="ED" mediaType="image/jpeg">
                                    <reference value="intuniv-02.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="56bb0a34-e656-4ffc-a819-6c7ad2df0aac"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Dose Proportionality</content>
                              </paragraph>
                              <paragraph>Following administration of INTUNIV in single doses of 1 mg, 2 mg, 3 mg, and 4 mg to adults, C<sub>max</sub> and AUC<sub>0-∞</sub> of guanfacine were proportional to dose.</paragraph>
                           </text>
                           <effectiveTime value="20250408"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="d660326d-18a7-4689-93af-e702a6623102"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Metabolism and Elimination</content>
                              </paragraph>
                              <paragraph>In vitro studies with human liver microsomes and recombinant CYP's demonstrated that guanfacine was primarily metabolized by CYP3A4. In pooled human hepatic microsomes, guanfacine did not inhibit the activities of the major cytochrome P450 isoenzymes (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4/5); guanfacine is also not an inducer of CYP3A, CYP1A2, and CYP2B6. Guanfacine is a substrate of CYP3A4/5 and exposure is affected by CYP3A4/5 inducers/inhibitors.</paragraph>
                              <paragraph>Guanfacine inhibits MATE1 and OCT1, but does not inhibit BSEP, MRP2, OATP1B1, OATP1B3, OAT1, OAT3, OCT2, or MATE2K. Guanfacine is a substrate of OCT1 and OCT2, but not BCRP, OATP1B1, OATP1B3, OAT1, OAT3, MATE1, or MATE2. Concomitant administration of guanfacine with OCT1 substrates might potentially increase the exposure of these OCT1 substrates.</paragraph>
                           </text>
                           <effectiveTime value="20250408"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="bab9b990-76cd-408c-86ff-df50c23297cf"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Studies in Specific Populations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250408"/>
                           <component>
                              <section>
                                 <id root="9e28f448-c056-420c-8b0d-eee0f8dfc306"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline">Renal Impairment</content>
                                    </paragraph>
                                    <paragraph>The impact of renal impairment on the pharmacokinetics of guanfacine in children was not assessed. In adult patients with impaired renal function, the cumulative urinary excretion of guanfacine and the renal clearance diminished as renal function decreased. In patients on hemodialysis, the dialysis clearance was about 15% of the total clearance. The low dialysis clearance suggests that the hepatic elimination (metabolism) increases as renal function decreases.</paragraph>
                                 </text>
                                 <effectiveTime value="20250408"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="970a8b66-5fbb-4063-a6cd-2436e46039cf"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline">Hepatic Impairment</content>
                                    </paragraph>
                                    <paragraph>The impact of hepatic impairment on PK of guanfacine in children was not assessed. Guanfacine in adults is cleared both by the liver and the kidney, and approximately 50% of the clearance of guanfacine is hepatic <content styleCode="italics">[see <linkHtml href="#S8.7">Hepatic Impairment (8.7)</linkHtml>]</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20250408"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="e9e06e5d-dc3c-4061-8fda-1f12d7f10e0f"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline">Drug Interaction Studies</content>
                                    </paragraph>
                                    <paragraph>Guanfacine is primarily metabolized by CYP3A4 and its plasma concentrations can be affected significantly by CYP3A4 inhibitors or inducers (Figure 2).</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Figure 2: Effect of Other Drugs on the Pharmacokinetics (PK) of INTUNIV
													</content>
                                    </paragraph>
                                    <renderMultiMedia referencedObject="MM3"/>
                                    <paragraph>Guanfacine does not significantly affect exposures of methylphenidate and lisdexamfetamine when coadministered (Figure 3).</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Figure 3: Effect of INTUNIV on the Pharmacokinetics (PK) of Other Drugs</content>
                                    </paragraph>
                                    <paragraph>
                                       <renderMultiMedia referencedObject="MM4"/>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250408"/>
                                 <component>
                                    <observationMedia ID="MM3">
                                       <text>Figure 2</text>
                                       <value xsi:type="ED" mediaType="image/jpeg">
                                          <reference value="intuniv-03.jpg"/>
                                       </value>
                                    </observationMedia>
                                 </component>
                                 <component>
                                    <observationMedia ID="MM4">
                                       <text>Figure 3</text>
                                       <value xsi:type="ED" mediaType="image/jpeg">
                                          <reference value="intuniv-04.jpg"/>
                                       </value>
                                    </observationMedia>
                                 </component>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="306ddaeb-61c2-4f43-923a-17de42e35c42"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13	NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250408"/>
               <component>
                  <section ID="S13.1">
                     <id root="01664bc5-74c1-48c8-885e-0907929630b2"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <effectiveTime value="20250408"/>
                     <component>
                        <section>
                           <id root="f0bda992-5f2a-451b-99c5-f8cc1f7340d5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Carcinogenesis</content>
                              </paragraph>
                              <paragraph>No carcinogenic effect of guanfacine was observed in studies of 78 weeks in mice or 102 weeks in rats at doses up to 6.8 times the maximum recommended human dose of 0.12 mg/kg/day on a mg/m<sup>2</sup> basis.</paragraph>
                           </text>
                           <effectiveTime value="20250408"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="8860410b-6a82-4b25-a87c-eb0b4a4705d2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Mutagenesis</content>
                              </paragraph>
                              <paragraph>Guanfacine was not genotoxic in a variety of test models, including the Ames test and an <content styleCode="italics">in vitro</content> chromosomal aberration test; however, a marginal increase in numerical aberrations (polyploidy) was observed in the latter study.</paragraph>
                           </text>
                           <effectiveTime value="20250408"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="f3eef916-b57e-4f5c-ae75-a5035bb64353"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Impairment of Fertility</content>
                              </paragraph>
                              <paragraph>No adverse effects were observed in fertility studies in male and female rats at doses up to 22 times the maximum recommended human dose on a mg/m<sup>2 </sup>basis.</paragraph>
                           </text>
                           <effectiveTime value="20250408"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="1084cec8-d2c5-4e1f-aa81-123ce7afe082"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14	CLINICAL STUDIES</title>
               <text>
                  <paragraph>Efficacy of INTUNIV in the treatment of ADHD was established in children and adolescents (6 to 17 years) in:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Five short-term, placebo-controlled monotherapy trials (Studies 1, 2, 4, 5, and 6).</item>
                     <item>One short-term, placebo-controlled adjunctive trial with psychostimulants (Study 3).</item>
                     <item>One long-term, placebo-controlled monotherapy maintenance trial (Study 7). </item>
                  </list>
               </text>
               <effectiveTime value="20250408"/>
               <component>
                  <section>
                     <id root="6c837f15-b2c7-4b86-b605-f716b16bad06"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Studies 1 and 2: Fixed-dose INTUNIV Monotherapy</content>
                        </paragraph>
                        <paragraph>Study 1 (301 study) was a double-blind, placebo-controlled, parallel-group, fixed-dose study, in which efficacy of once daily dosing with INTUNIV (2 mg, 3 mg, and 4 mg) was evaluated for 5 weeks (n=345) in children and adolescents aged 6 to 17 years. Study 2 (304 study) was a double-blind, placebo-controlled, parallel-group, fixed-dose study, in which efficacy of once daily dosing with INTUNIV (1 mg, 2 mg, 3 mg, and 4 mg) was evaluated for 6 weeks (n=324) in children and adolescents aged 6 to 17 years. In both studies, randomized patients in 2 mg, 3 mg, and 4 mg dose groups were titrated to their target fixed dose, and continued on the same dose until a dose tapering phase started. The lowest dose of 1 mg used in Study 2 was not randomized to patients weighing more than 50 kg. Patients who weighed less than 25 kg were not included in either study.</paragraph>
                        <paragraph>Signs and symptoms of ADHD were evaluated on a once weekly basis using the clinician administered and scored ADHD Rating Scale (ADHD-RS-IV), which includes both hyperactive/impulsive and inattentive subscales. The primary efficacy outcome was the change from baseline to endpoint in ADHD-RS-IV total scores. Endpoint was defined as the last post-randomization treatment week for which a valid score was obtained prior to dose tapering (up to Week 5 in Study 1 and up to Week 6 in Study 2).</paragraph>
                        <paragraph>The mean reductions in ADHD-RS-IV total scores at endpoint were statistically significantly greater for INTUNIV compared to placebo for Studies 1 and 2. Placebo-adjusted changes from baseline were statistically significant for each of the 2 mg, 3 mg, and 4 mg INTUNIV randomized treatment groups in both studies, as well as the 1 mg INTUNIV treatment group that was included only in Study 2 (see <linkHtml href="#table16">Table 16</linkHtml>).</paragraph>
                        <paragraph>Dose-responsive efficacy was evident, particularly when data were examined on a weight-adjusted (mg/kg) basis. When evaluated over the dose range of 0.01 to 0.17 mg/kg/day, clinically relevant improvements were observed beginning at doses in the range 0.05 to-0.08 mg/kg/day. Doses up to 0.12 mg/kg/day were shown to provide additional benefit.</paragraph>
                        <paragraph>In the monotherapy trials (Studies 1 and 2), subgroup analyses were performed to identify any differences in response based on gender or age (6 to 12 vs. 13 to 17). Analyses of the primary outcome did not suggest any differential responsiveness on the basis of gender. Analyses by age revealed a statistically significant treatment effect only in the 6 to 12 age subgroup. Due to the relatively small proportion of adolescent patients (ages 13 to 17) enrolled into these studies (approximately 25%), these data may not have been sufficient to demonstrate efficacy in the adolescent patients. In these studies, patients were randomized to a fixed dose of INTUNIV rather than optimized by body weight. Therefore, some adolescent patients were randomized to a dose that might have resulted in relatively lower plasma guanfacine concentrations compared to the younger patients. Over half (55%) of the adolescent patients received doses of 0.01 to 0.04 mg/kg. In studies in which systematic pharmacokinetic data were obtained, there was a strong inverse correlation between body weight and plasma guanfacine concentrations.</paragraph>
                        <table width="100%" ID="table16">
                           <caption>Table 16: Fixed dose Studies</caption>
                           <col width="20%" align="left" valign="top"/>
                           <col width="20%" align="left" valign="top"/>
                           <col width="20%" align="center" valign="top"/>
                           <col width="20%" align="center" valign="top"/>
                           <col width="20%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th rowspan="2">Study Number<br/>(Age Range)</th>
                                 <th align="center">Treatment Group</th>
                                 <th align="left" colspan="3" styleCode="Botrule">Primary Efficacy Measure: ADHD-RS-IV Total Score</th>
                              </tr>
                              <tr>
                                 <th/>
                                 <th align="center">Mean Baseline Score (SD)</th>
                                 <th align="center">LS Mean Change from Baseline (SE)</th>
                                 <th align="center">Placebo-subtracted Difference<footnote ID="t16fa">Difference (drug minus placebo) in least-squares mean change from baseline.</footnote> (95% CI)</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td align="left" valign="top" colspan="5">SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: unadjusted confidence interval.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule" rowspan="4">Study 1<br/>(6 to 17 years)</td>
                                 <td>INTUNIV  2 mg<footnote ID="t16f1">Doses statistically significantly superior to placebo.</footnote>
                                 </td>
                                 <td>36.1 (9.99)</td>
                                 <td>-15.9 (1.37)</td>
                                 <td>-7.4 (-11.3, -3.5)</td>
                              </tr>
                              <tr>
                                 <td>INTUNIV  3 mg<footnoteRef IDREF="t16f1"/>
                                 </td>
                                 <td align="center">36.8 (8.72)</td>
                                 <td>-16.0 (1.38)</td>
                                 <td>-7.5 (-11.4, -3.6)</td>
                              </tr>
                              <tr>
                                 <td>INTUNIV  4 mg<footnoteRef IDREF="t16f1"/>
                                 </td>
                                 <td align="center">38.4 (9.21)</td>
                                 <td>-18.5 (1.39)</td>
                                 <td>-10.0 (-13.9, -6.1)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td>Placebo</td>
                                 <td align="center">38.1 (9.34)</td>
                                 <td>-8.5 (1.42)</td>
                                 <td>--</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule" rowspan="5">Study 2<br/>(6 to 17 years)</td>
                                 <td>INTUNIV  1 mg<footnoteRef IDREF="t16f1"/>
                                    <footnote ID="t16f2">The lowest dose of 1 mg used in Study 2 was not randomized to patients weighing more than 50 kg.</footnote>
                                 </td>
                                 <td>41.7 (7.81)</td>
                                 <td>-19.4 (1.69)</td>
                                 <td>-6.8 (-11.3, -2.2)</td>
                              </tr>
                              <tr>
                                 <td>INTUNIV  2 mg<footnoteRef IDREF="t16f1"/>
                                 </td>
                                 <td align="center">39.9 (8.74)</td>
                                 <td>-18.1 (1.60)</td>
                                 <td>-5.4 (-9.9, -0.9)</td>
                              </tr>
                              <tr>
                                 <td>INTUNIV  3 mg<footnoteRef IDREF="t16f1"/>
                                 </td>
                                 <td align="center">39.1 (9.22)</td>
                                 <td>-20.0 (1.64)</td>
                                 <td>-7.3 (-11.8, -2.8)</td>
                              </tr>
                              <tr>
                                 <td>INTUNIV  4 mg<footnoteRef IDREF="t16f1"/>
                                 </td>
                                 <td align="center">40.6 (8.57)</td>
                                 <td>-20.6 (1.60)</td>
                                 <td>-7.9 (-12.3, -3.4)</td>
                              </tr>
                              <tr>
                                 <td>Placebo</td>
                                 <td align="center">39.3 (8.85)</td>
                                 <td>-12.7 (1.60)</td>
                                 <td>--</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250408"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2b53bc07-c982-486b-bfbe-bbc446e7cce1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Study 3: Flexible-dose INTUNIV as Adjunctive Therapy to Psychostimulants</content>
                        </paragraph>
                        <paragraph>Study 3 (313 study) was a double-blind, randomized, placebo-controlled, dose-optimization study, in which efficacy of once daily optimized dosing (morning or evening) with INTUNIV (1 mg, 2 mg, 3 mg, and 4 mg), when co-administered with psychostimulants, was evaluated for 8 weeks, in children and adolescents aged 6 to 17 years with a diagnosis of ADHD, with a sub-optimal response to stimulants (n=455). Patients were started at the 1 mg INTUNIV dose level and were titrated weekly over a 5-week dose-optimization period to an optimal INTUNIV dose not to exceed 4 mg/day based on tolerability and clinical response. The dose was then maintained for a 3-week dose maintenance period before entry to 1 week of dose tapering. Patients took INTUNIV either in the morning or the evening while maintaining their current dose of psychostimulant treatment given each morning. Allowable psychostimulants in the study were ADDERALL XR<sup>®</sup>, VYVANSE<sup>®</sup>, CONCERTA<sup>®</sup>, FOCALIN XR<sup>®</sup>, RITALIN LA<sup>®</sup>, METADATE CD<sup>®</sup>,or FDA-approved generic equivalents.</paragraph>
                        <paragraph>Symptoms of ADHD were evaluated on a weekly basis by clinicians using the ADHD Rating Scale (ADHD-RS-IV), which includes both hyperactive/impulsive and inattentive subscales. The primary efficacy outcome was the change from baseline to endpoint in ADHD-RS-IV total scores. Endpoint was defined as the last post-randomization treatment week prior to dose tapering for which a valid score was obtained (up to Week 8).</paragraph>
                        <paragraph>Mean reductions in ADHD-RS-IV total scores at endpoint were statistically significantly greater for INTUNIV given in combination with a psychostimulant compared to placebo given with a psychostimulant for Study 3, for both morning and evening INTUNIV dosing (see <linkHtml href="#table17">Table 17</linkHtml>). Nearly two-thirds (64.2%) of patients reached optimal doses in the 0.05 to 0.12 mg/kg/day range.</paragraph>
                     </text>
                     <effectiveTime value="20250408"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="00e4558d-2996-4689-825f-4068aa5e6b90"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Studies 4, 5, and 6: Flexible-dose INTUNIV Monotherapy</content>
                        </paragraph>
                        <paragraph>Study 4 (314 study) was a double-blind, randomized, placebo-controlled, dose-optimization study, in which efficacy of once daily dosing (morning or evening) with INTUNIV (1 mg, 2 mg, 3 mg, and 4 mg) was evaluated for 8 weeks in children aged 6 to 12 years (n=340).</paragraph>
                        <paragraph>Signs and symptoms of ADHD were evaluated on a once weekly basis using the clinician administered and scored ADHD Rating Scale (ADHD-RS-IV), which includes both hyperactive/impulsive and inattentive subscales. The primary efficacy outcome was the change from baseline score at endpoint on the ADHD-RS-IV total scores. Endpoint was defined as the last post-randomization treatment week for which a valid score was obtained prior to dose tapering (up to Week 8).</paragraph>
                        <paragraph>Mean reductions in ADHD-RS-IV total scores at endpoint were statistically significantly greater for INTUNIV compared to placebo in both AM and PM dosing groups of INTUNIV (see <linkHtml href="#table17">Table 17</linkHtml>).</paragraph>
                        <paragraph>Study 5 (312 study) was a 15-week, double-blind, randomized, placebo-controlled, dose-optimization study conducted in adolescents aged 13 to 17 years (n=314) to evaluate the efficacy and safety of INTUNIV (1 to 7 mg/day; optimized dose range of 0.05 to 0.12 mg/kg/day) in the treatment of ADHD as measured by the ADHD Rating Scale-IV (ADHD-RS-IV). Patients receiving INTUNIV showed statistically significantly greater improvement on the ADHD-RS-IV total score compared with patients receiving placebo (see <linkHtml href="#table17">Table 17</linkHtml>).</paragraph>
                        <paragraph>Study 6 (316 study) was a 12-week (for children aged 6 to 12) or 15-week (for adolescents aged 13 to 17), randomized, double-blind, parallel-group, placebo- and active-reference, dose-optimization study conducted in pediatric patients (children and adolescents aged 6 to 17 years old inclusive) (n=337) to assess the efficacy and safety of once-daily dosing (children: 1 to 4 mg/day, adolescents: 1 to 7 mg/day; optimized dose range of 0.05 to 0.12 mg/kg/day) in the treatment of ADHD. INTUNIV was statistically superior to placebo on symptoms of ADHD in patients 6 to 17 years as measured by change from baseline in ADHD-RS-IV total scores (see <linkHtml href="#table17">Table 17</linkHtml>).</paragraph>
                        <table width="100%" ID="table17">
                           <caption>Table 17: Flexible-Dose studies</caption>
                           <col width="15%" align="left" valign="top"/>
                           <col width="25%" align="left" valign="top"/>
                           <col width="20%" align="center" valign="middle"/>
                           <col width="20%" align="center" valign="middle"/>
                           <col width="20%" align="center" valign="middle"/>
                           <thead>
                              <tr styleCode="Botrule">
                                 <th rowspan="2">Study Number<br/>(Age Range)</th>
                                 <th rowspan="2">Treatment Group</th>
                                 <th colspan="3" align="left">Primary Efficacy Measure: ADHD-RS-IV Total Score</th>
                              </tr>
                              <tr>
                                 <th align="center">Mean Baseline Score (SD)</th>
                                 <th align="center">LS Mean Change from Baseline (SE)</th>
                                 <th>Placebo-subtracted Difference<footnote ID="t17fb">Difference (drug minus placebo) in least-squares mean change from baseline.</footnote> (95% CI)</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td align="left" valign="top" colspan="5">SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: unadjusted confidence interval.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td rowspan="3" styleCode="Botrule">Study 3<footnote ID="t17fa">Treatment was given in combination with a psychostimulant.</footnote>
                                    <br/>(6 to 17 years)</td>
                                 <td>INTUNIV 1 to 4 mg AM<footnote ID="t17f1">Doses statistically significantly superior to placebo.</footnote>
                                 </td>
                                 <td>37.6 (8.13)</td>
                                 <td>-20.3 (0.97)</td>
                                 <td>-4.5 (-7.5, -1.4)</td>
                              </tr>
                              <tr>
                                 <td>INTUNIV 1 to 4 mg PM<footnoteRef IDREF="t17f1"/>
                                 </td>
                                 <td align="center">37.0 (7.65)</td>
                                 <td>-21.2 (0.97)</td>
                                 <td>-5.3 (-8.3, -2.3)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td>Placebo</td>
                                 <td align="center">37.7 (7.75)</td>
                                 <td>-15.9 (0.96)</td>
                                 <td>--</td>
                              </tr>
                              <tr>
                                 <td rowspan="3" styleCode="Botrule">Study 4<br/>(6 to 12 years)</td>
                                 <td>INTUNIV 1 to 4 mg AM<footnoteRef IDREF="t17f1"/>
                                 </td>
                                 <td>41.7 (6.39)</td>
                                 <td>-20.0 (1.23)</td>
                                 <td>-9.4 (-12.8, -6.0)</td>
                              </tr>
                              <tr>
                                 <td>INTUNIV 1 to 4 mg PM<footnoteRef IDREF="t17f1"/>
                                 </td>
                                 <td align="center">41.6 (6.66)</td>
                                 <td>-20.4 (1.19)</td>
                                 <td>-9.8 (-13.1, -6.4)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td>Placebo</td>
                                 <td align="center">42.9 (6.29)</td>
                                 <td>-10.6 (1.20)</td>
                                 <td>--</td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode="Botrule">Study 5<br/>(13 to 17 years)</td>
                                 <td>INTUNIV 1 to 7 mg<footnoteRef IDREF="t17f1"/>
                                 </td>
                                 <td>39.9 (5.57)</td>
                                 <td>-24.6 (1.06)</td>
                                 <td>-6.03 (-8.87, -3.19)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td>Placebo</td>
                                 <td align="center">40.0 (6.11)</td>
                                 <td>-18.5 (1.08)</td>
                                 <td>--</td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode="Botrule">Study 6<br/>(6 to 17 years)</td>
                                 <td>INTUNIV 1 to 7 mg<footnoteRef IDREF="t17f1"/>
                                 </td>
                                 <td>43.1 (5.47)</td>
                                 <td>-23.89 (1.15)</td>
                                 <td>-8.88 (-11.94, -5.81)</td>
                              </tr>
                              <tr>
                                 <td>Placebo</td>
                                 <td align="center">43.2 (5.60)</td>
                                 <td>-15.01 (1.16)</td>
                                 <td>--</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250408"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="5c725d78-02d6-4576-b1fb-b9e712028c8a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Study 7: Long-Term Maintenance of INTUNIV Efficacy</content>
                        </paragraph>
                        <paragraph>Study 7 (315 study) was a double-blind, placebo-controlled, randomized withdrawal trial in pediatric patients aged 6 to 17 years with DSM-IV-TR diagnosis of ADHD.  The study consisted of an open-label phase, including a 7-week dose optimization period to titrate patients to an optimal dose (maximum 4 mg/day for children and 7 mg/day for adolescents; optimized dose range: 0.05 to 0.12 mg/kg/day) and a 6-week dose maintenance period. There were 526 patients included in the open-label phase. Among those, 315 patients who met response criteria in the open-label phase were then randomized (1:1, INTUNIV:placebo) in a 26-week, double-blind, randomized withdrawal phase. The response criteria were defined by ≥30% reduction in ADHD-RS-IV total score and a Clinical Global Impression-Improvement (CGI-I) score of 1 or 2 during the open-label phase.  A statistically significantly lower proportion of treatment failures occurred among INTUNIV patients compared to placebo at the end of the randomized withdrawal period (Figure 4). Treatment failure was defined as a ≥50% increase (worsening) in ADHD-RS-IV total score and a ≥2-point increase in Clinical Global Impression-Severity (CGI-S) score. Patients who met the treatment failure criteria on two consecutive visits or discontinued for any reason were classified as treatment failure.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 4. Kaplan-Meier Estimation of Proportion of Patients with Treatment Failure for Children and Adolescents Ages 6 to 17 (Study 7)</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM5"/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250408"/>
                     <component>
                        <observationMedia ID="MM5">
                           <text>Figure 3</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="intuniv-05.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="b2589199-7982-4588-90b9-f52922c69383"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>INTUNIV is supplied in 1 mg, 2 mg, 3 mg, and 4 mg strength extended-release tablets in 100 count bottles.</paragraph>
                  <table width="75%">
                     <col width="20%" align="left" valign="top"/>
                     <col width="20%" align="left" valign="top"/>
                     <col width="20%" align="left" valign="top"/>
                     <col width="20%" align="left" valign="top"/>
                     <col width="20%" align="left" valign="top"/>
                     <thead>
                        <tr>
                           <th styleCode="Lrule Rrule"/>
                           <th styleCode="Rrule">1 mg</th>
                           <th styleCode="Rrule">2 mg</th>
                           <th styleCode="Rrule">3 mg</th>
                           <th styleCode="Rrule">4 mg</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="bold">Color</content>
                           </td>
                           <td styleCode="Rrule">White/off-white</td>
                           <td styleCode="Rrule">White/off-white</td>
                           <td styleCode="Rrule">Green</td>
                           <td styleCode="Rrule">Green</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="bold">Shape</content>
                           </td>
                           <td styleCode="Rrule">Round</td>
                           <td styleCode="Rrule">Caplet</td>
                           <td styleCode="Rrule">Round</td>
                           <td styleCode="Rrule">Caplet</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="bold">Debossment<br/>(top/bottom)</content>
                           </td>
                           <td styleCode="Rrule">503 / 1 mg</td>
                           <td styleCode="Rrule">503 / 2 mg</td>
                           <td styleCode="Rrule">503 / 3 mg</td>
                           <td styleCode="Rrule">503 / 4 mg</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule">
                              <content styleCode="bold">NDC number</content>
                           </td>
                           <td styleCode="Rrule">54092-513-02</td>
                           <td styleCode="Rrule">54092-515-02</td>
                           <td styleCode="Rrule">54092-517-02</td>
                           <td styleCode="Rrule">54092-519-02</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250408"/>
               <component>
                  <section>
                     <id root="a7a3c0f0-e5a0-4e73-8b53-3c5b695a0c6a"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Storage</content> - Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). See USP Controlled Room Temperature.</paragraph>
                     </text>
                     <effectiveTime value="20250408"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="a6d1b9d6-4011-4d3d-ad61-d2d7b0851a24"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (<linkHtml href="#PI">Patient Information</linkHtml>).</paragraph>
               </text>
               <effectiveTime value="20250408"/>
               <component>
                  <section>
                     <id root="f6fed0d3-30fa-4b52-917c-3f0edd253b72"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Dosing and Administration</content>
                        </paragraph>
                        <paragraph>Instruct patients to swallow INTUNIV whole with water, milk, or other liquid. <content styleCode="underline">Tablets should not be crushed, chewed or broken prior to administration because this may increase the rate of release of the active drug<content styleCode="italics">.</content> </content>Patients should not take INTUNIV together with a high-fat meal, since this can raise blood levels of INTUNIV. Instruct the parent or caregiver to supervise the child or adolescent taking INTUNIV and to keep the bottle of tablets out of reach of children.</paragraph>
                        <paragraph>Advise patients not to abruptly discontinue INTUNIV as abrupt discontinuation can result in clinically significant rebound hypertension. Concomitant stimulant use and abrupt discontinuation of INTUNIV may increase this hypertensive response. Instruct patients on how to properly taper the dose to minimize the risk of rebound hypertension <content styleCode="italics">[see <linkHtml href="#S2.5">Dosage and Administration (2.5)</linkHtml> and <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250408"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="3aeea05f-f7bb-4d40-8acc-c08f2f691746"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Adverse Reactions</content>
                        </paragraph>
                        <paragraph>Advise patients that sedation can occur, particularly early in treatment or with dose increases. Caution against operating heavy equipment or driving until they know how they respond to treatment with INTUNIV
									<content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>].</content> Headache and abdominal pain can also occur. If any of these symptoms persist, or other symptoms occur, the patient should be advised to discuss the symptoms with the health care provider.</paragraph>
                        <paragraph>Advise patients to avoid becoming dehydrated or overheated, which may potentially increase the risks of hypotension and syncope <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>. Advise patients to avoid use with alcohol.</paragraph>
                     </text>
                     <effectiveTime value="20250408"/>
                     <component>
                        <section>
                           <id root="58170166-bf07-43d1-bdce-b05b65c7ffca"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>Pregnancy Registry</paragraph>
                              <paragraph>Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in patients exposed to INTUNIV during pregnancy <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>].</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250408"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="8aab3bc6-7afb-4528-81e1-755a5392559e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lactation</content>
                        </paragraph>
                        <paragraph>Advise breastfeeding mothers to monitor infants exposed to guanfacine through breastmilk for sedation, lethargy, and poor feeding <content styleCode="italics">[see <linkHtml href="#S8.2">Use in Specific Populations (8.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250408"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="PI">
               <id root="1559f912-c41e-4464-8b64-15a8165ae698"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <title>Patient Information</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">INTUNIV<sup>®</sup> (in-TOO-niv)<br/>(guanfacine)<br/>Extended-Release Tablets</content>
                  </paragraph>
                  <paragraph>Read the Patient Information that comes with INTUNIV before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your medical condition or your treatment.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What is INTUNIV</content>
                     <content styleCode="bold">? </content>
                  </paragraph>
                  <paragraph>INTUNIV is a prescription medicine used to treat the symptoms of attention deficit hyperactivity disorder (ADHD). INTUNIV may be used alone or with ADHD stimulant medicines.</paragraph>
                  <paragraph>INTUNIV is not a central nervous system (CNS) stimulant.</paragraph>
                  <paragraph>It is not known if INTUNIV is safe and effective in children younger than 6 years of age.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Who should not take INTUNIV</content>
                     <content styleCode="bold">?</content>
                  </paragraph>
                  <paragraph>Do not take INTUNIV if you are allergic to guanfacine or any of the ingredients in INTUNIV. See the end of this leaflet for a complete list of ingredients in INTUNIV.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What should I tell my doctor before taking INTUNIV</content>
                     <content styleCode="bold">?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Before you take INTUNIV</content>
                     <content styleCode="bold">, tell your doctor if you:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>have heart problems or a low heart rate</item>
                     <item>have fainted</item>
                     <item>have low or high blood pressure</item>
                     <item>have liver or kidney problems</item>
                     <item>have any other medical conditions</item>
                     <item>are pregnant or plan to become pregnant. It is not known if INTUNIV will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. 							<list listType="unordered" styleCode="circle">
                           <item>There is a pregnancy registry for females who are exposed to ADHD medications, including INTUNIV, during pregnancy. The purpose of the registry is to collect information about the health of females exposed to INTUNIV and their baby. If you or your child becomes pregnant during treatment with INTUNIV, talk to your healthcare provider about registering with the National Pregnancy Registry of ADHD medications at 1-866-961-2388.</item>
                        </list>
                     </item>
                     <item>are breastfeeding or plan to breastfeed. It is not known if INTUNIV passes into your breast milk. Talk to your doctor about the best way to feed your baby while taking INTUNIV.</item>
                  </list>
                  <paragraph>Tell your doctor about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.</paragraph>
                  <paragraph>INTUNIV may affect the way other medicines work, and other medicines may affect how INTUNIV works.</paragraph>
                  <paragraph>Especially tell your doctor if you take: </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>ketoconazole</item>
                     <item>medicines that can affect enzyme metabolism</item>
                     <item>high blood pressure medicine</item>
                     <item>sedatives</item>
                     <item>benzodiazepines</item>
                     <item>barbiturates</item>
                     <item>antipsychotics</item>
                  </list>
                  <paragraph>Ask your doctor or pharmacist for a list of these medicines, if you are not sure.</paragraph>
                  <paragraph>Know the medicines you take. Keep a list of them and show it to your doctor and pharmacist when you get a new medicine.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I take INTUNIV</content>
                     <content styleCode="bold">?</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Take INTUNIV exactly as your doctor tells you.</item>
                     <item>Your doctor may change your dose. Do not change your dose of INTUNIV without talking to your doctor.</item>
                     <item>Do not stop taking INTUNIV without talking to your doctor.</item>
                     <item>Try not to miss your dose of INTUNIV. If you miss a dose of INTUNIV, take the next dose at your regular time. If you miss 2 or more doses, talk to your doctor, as you may need to restart INTUNIV with a lower dose.</item>
                     <item>Do not take a double dose to make up for a missed dose.</item>
                     <item>INTUNIV should be taken 1 time a day in the morning or in the evening, either alone or in combination with an ADHD stimulant medicine that your doctor may prescribe. Your doctor will tell you when to take INTUNIV and when to take your ADHD stimulant medication.</item>
                     <item>INTUNIV should be swallowed whole with a small amount of water, milk, or other liquid.</item>
                     <item>Do not crush, chew, or break INTUNIV. Tell your doctor if you cannot swallow INTUNIV whole.</item>
                     <item>Do not take INTUNIV with a high-fat meal.</item>
                     <item>Your doctor will check your blood pressure and heart rate while you take INTUNIV.</item>
                     <item>If you take too much INTUNIV, call your local Poison Control Center at 1-800-222-1222 or go to the nearest emergency room right away.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">What should I avoid while taking INTUNIV</content>
                     <content styleCode="bold">?</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Do not drive, operate heavy machinery, or do other dangerous activities until you know how INTUNIV affects you. INTUNIV can slow your thinking and motor skills.</item>
                     <item>Do not drink alcohol or take other medicines that make you sleepy or dizzy while taking INTUNIV until you talk with your doctor. INTUNIV taken with alcohol or medicines that cause sleepiness or dizziness may make your sleepiness or dizziness worse.</item>
                     <item>Do not become dehydrated or overheated. This may increase your chance of having low blood pressure or fainting while taking INTUNIV.</item>
                     <item>Do not suddenly stop INTUNIV. Tell your healthcare provider if you have been vomiting and cannot take INTUNIV, you may be at risk for rebound hypertension.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">What are the possible side effects of INTUNIV</content>
                     <content styleCode="bold">?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">INTUNIV</content>
                     <content styleCode="bold"> may cause serious side effects including:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>low blood pressure</item>
                     <item>low heart rate</item>
                     <item>fainting</item>
                     <item>sleepiness</item>
                     <item>increased blood pressure and heart rate after suddenly stopping INTUNIV (rebound hypertension). Suddenly stopping INTUNIV can cause increased blood pressure and heart rate and other withdrawal symptoms such as headache, confusion, nervousness, agitation, and tremors. If these symptoms continue to get worse and are left untreated, it could lead to a very serious condition including very high blood pressure, feeling very sleepy or tired, severe headache, vomiting, vision problems, seizures.</item>
                  </list>
                  <paragraph>Get medical help right away, if you have any of the symptoms listed above.</paragraph>
                  <paragraph>
                     <content styleCode="bold">The most common side effects of INTUNIV</content>
                     <content styleCode="bold"> include:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>sleepiness</item>
                     <item>tiredness</item>
                     <item>trouble sleeping</item>
                     <item>low blood pressure</item>
                     <item>nausea</item>
                     <item>stomach pain</item>
                     <item>dizziness</item>
                     <item>dry mouth</item>
                     <item>irritability</item>
                     <item>vomiting</item>
                     <item>slow heart rate</item>
                  </list>
                  <paragraph>Tell the doctor if you have any side effect that bothers you or that does not go away.</paragraph>
                  <paragraph>These are not all the possible side effects of INTUNIV. For more information, ask your doctor or pharmacist.</paragraph>
                  <paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I store INTUNIV</content>
                     <content styleCode="bold">?</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Store INTUNIV between 68°F to 77°F (20°C to 25°C)</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Keep INTUNIV</content>
                     <content styleCode="bold"> and all medicines out of the reach of children.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">General Information about the safe and effective use INTUNIV</content>
                  </paragraph>
                  <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information Leaflet. Do not use INTUNIV for a condition for which it was not prescribed. Do not give INTUNIV to other people, even if they have the same symptoms that you have. It may harm them.</paragraph>
                  <paragraph>This leaflet summarizes the most important information about INTUNIV. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about INTUNIV that is written for health professionals.</paragraph>
                  <paragraph>For more information, go to <content styleCode="bold">
                        <content styleCode="underline">www.INTUNIV.com</content> or call 1-877-825-3327.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the ingredients in INTUNIV</content>
                     <content styleCode="bold">?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Active ingredient: </content>guanfacine hydrochloride</paragraph>
                  <paragraph>
                     <content styleCode="bold">Inactive ingredients: </content>hypromellose, methacrylic acid copolymer, lactose, povidone, crospovidone, microcrystalline cellulose, fumaric acid, and glycerol behenate. In addition, the 3 mg and 4 mg tablets also contain green pigment blend PB-1763.</paragraph>
                  <paragraph>
                     <content styleCode="bold">This Patient Information has been approved by the U.S. Food and Drug Administration.</content>
                  </paragraph>
                  <paragraph>Distributed by:<br/> Takeda Pharmaceuticals America, Inc.<br/>Cambridge, MA 02142</paragraph>
                  <paragraph>INTUNIV is a registered trademark of Takeda Pharmaceuticals U.S.A., Inc.</paragraph>
                  <paragraph>© 2025 Takeda Pharmaceuticals U.S.A., Inc. All rights reserved.</paragraph>
                  <paragraph>Patented: see www.takeda.com/en-us/patents.</paragraph>
                  <paragraph>Revised: 4/2025</paragraph>
               </text>
               <effectiveTime value="20250408"/>
            </section>
         </component>
         <component>
            <section>
               <id root="d2515d65-76a1-4534-bc55-70edadcfbc85"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 1 mg Tablet Bottle Label</title>
               <text>
                  <paragraph>NDC 54092-513-02</paragraph>
                  <paragraph>
                     <content styleCode="bold">intuniv<sup>®</sup>
                     </content>
                     <br/> (guanfacine)<br/> Extended-Release Tablets</paragraph>
                  <paragraph>
                     <content styleCode="bold">100 Tablets<br/> 1 mg<br/> Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Each tablet contains:</content> 1 mg of guanfacine, as guanfacine HCl</paragraph>
                  <paragraph>Tablets should not be crushed,<br/> chewed or broken before swallowing.</paragraph>
                  <paragraph>Distributed by:<br/> Takeda Pharmaceuticals<br/> America, Inc.<br/>Cambridge, MA 02142</paragraph>
                  <paragraph>
                     <content styleCode="bold italics">Takeda</content>
                  </paragraph>
                  <paragraph>Product of Spain</paragraph>
                  <renderMultiMedia referencedObject="MM6"/>
               </text>
               <effectiveTime value="20250408"/>
               <component>
                  <observationMedia ID="MM6">
                     <text>PRINCIPAL DISPLAY PANEL - 1 mg Tablet Bottle Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="intuniv-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="05160e7d-bf8e-4563-839d-38c7fa16c6a1"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 2 mg Tablet Bottle Label</title>
               <text>
                  <paragraph>NDC 54092-515-02</paragraph>
                  <paragraph>
                     <content styleCode="bold">intuniv<sup>®</sup>
                     </content>
                     <br/> (guanfacine)<br/> Extended-Release Tablets</paragraph>
                  <paragraph>
                     <content styleCode="bold">100 Tablets<br/> 2 mg<br/> Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Each tablet contains:</content> 2 mg of guanfacine, as guanfacine HCl</paragraph>
                  <paragraph>Tablets should not be crushed,<br/> chewed or broken before swallowing.</paragraph>
                  <paragraph>Distributed by:<br/> Takeda Pharmaceuticals<br/> America, Inc.<br/>Cambridge, MA 02142</paragraph>
                  <paragraph>
                     <content styleCode="bold italics">Takeda</content>
                  </paragraph>
                  <paragraph>Product of Spain</paragraph>
                  <renderMultiMedia referencedObject="MM7"/>
               </text>
               <effectiveTime value="20250408"/>
               <component>
                  <observationMedia ID="MM7">
                     <text>PRINCIPAL DISPLAY PANEL - 2 mg Tablet Bottle Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="intuniv-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="8c5a801f-bf1d-4ff8-bef9-6e545fc72c2d"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 3 mg Tablet Bottle Label</title>
               <text>
                  <paragraph>NDC 54092-517-02</paragraph>
                  <paragraph>
                     <content styleCode="bold">intuniv<sup>®</sup>
                     </content>
                     <br/> (guanfacine)<br/> Extended-Release Tablets</paragraph>
                  <paragraph>
                     <content styleCode="bold">100 Tablets<br/> 3 mg<br/> Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Each tablet contains:</content> 3 mg of guanfacine, as guanfacine HCl</paragraph>
                  <paragraph>Tablets should not be crushed,<br/> chewed or broken before swallowing.</paragraph>
                  <paragraph>Distributed by:<br/> Takeda Pharmaceuticals<br/> America, Inc.<br/>Cambridge, MA 02142</paragraph>
                  <paragraph>
                     <content styleCode="bold italics">Takeda</content>
                  </paragraph>
                  <paragraph>Product of Spain</paragraph>
                  <renderMultiMedia referencedObject="MM8"/>
               </text>
               <effectiveTime value="20250408"/>
               <component>
                  <observationMedia ID="MM8">
                     <text>PRINCIPAL DISPLAY PANEL - 3 mg Tablet Bottle Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="intuniv-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="d22c1e6f-5690-4453-aad5-12f575ab35cf"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 4 mg Tablet Bottle Label</title>
               <text>
                  <paragraph>NDC 54092-519-02</paragraph>
                  <paragraph>
                     <content styleCode="bold">intuniv<sup>®</sup>
                     </content>
                     <br/> (guanfacine)<br/> Extended-Release Tablets</paragraph>
                  <paragraph>
                     <content styleCode="bold">100 Tablets<br/> 4 mg<br/> Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Each tablet contains:</content> 4 mg of guanfacine, as guanfacine HCl</paragraph>
                  <paragraph>Tablets should not be crushed,<br/> chewed or broken before swallowing.</paragraph>
                  <paragraph>Distributed by:<br/> Takeda Pharmaceuticals<br/> America, Inc.<br/>Cambridge, MA 02142</paragraph>
                  <paragraph>
                     <content styleCode="bold italics">Takeda</content>
                  </paragraph>
                  <paragraph>Product of Spain</paragraph>
                  <renderMultiMedia referencedObject="MM9"/>
               </text>
               <effectiveTime value="20250408"/>
               <component>
                  <observationMedia ID="MM9">
                     <text>PRINCIPAL DISPLAY PANEL - 4 mg Tablet Bottle Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="intuniv-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="66fbd5b6-c1b5-431b-9d80-f8fea358dada"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - NDC 54092-520-01</title>
               <text>
                  <paragraph>Image not Available</paragraph>
                  <renderMultiMedia referencedObject="MM10"/>
               </text>
               <effectiveTime value="20250408"/>
               <component>
                  <observationMedia ID="MM10">
                     <text>PRINCIPAL DISPLAY PANEL - NDC 54092-520-01</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="intuniv-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>